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Leveraging Aberrant Iron Metabolism as a Method for Selective Drug 
Delivery and Imaging In Vivo 
Ryan Muir 
Abstract 
Iron is a nutrient essential for cell growth and proliferation, however too high of a 
concentration can cause the formation of toxic reactive oxygen species. As a result, 
normal cells tightly regulate iron metabolism. Many cancers have been noted to 
possess aberrant expression of various proteins in the iron metabolism pathway, with a 
strong correlation between a higher avidity for iron and worse patient prognosis. 
Recently the Renslo lab has sought to leverage this elevated level of iron utilizing an 
Fe(II)-activated prodrug platform based on the reactivity of 1,2,4-trioxolanes (TRX). 
Previous studies have demonstrated selective delivery of amine-bearing cytotoxins to 
cancers with elevated Fe(II) pools. Here we report expanding this work in three ways: 1. 
Design of a therapeutic diagnostic PET probe to identify potential suitable cancers for 
this TRX-based approach. 2. Delivery of targeted anticancer therapeutics in order to 
gain an additional level of selectivity. 3. Expanding the TRX scaffold to accommodate 
hydroxamate-containing chemotherapeutics. 
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Chapter 1: Mammalian Iron Metabolism 
	
Iron is an essential nutrient for cell growth and proliferation. Cells utilize the redox 
potential of Fe(II) to perform a variety of cellular processes, including respiration and 
dNTP production.1,2 However, free ferrous iron can also undergo Fenton chemistry with 
water or peroxides found within the cell to generate toxic reactive oxygen species 
(ROS).3 Therefore, iron metabolism must be highly regulated in normal, healthy tissues 
to provide a balance for enough Fe(II) to grow yet not so much as to induce oxidative 
stress on the cell. 
Iron primarily enters the cell through the transferrin receptor complex, in which 
transferrin bound to two molecules of ferric iron will be bind transferrin receptor and be 
endocytosed.4 Upon acidification of the endosome, the Fe(III) is released, reduced by 
STEAP3, and transported into the cytosol by the divalent metal transporter DMT1. From 
here, Fe(II) joins the labile iron pool and can behave as a cofactor in nuclear and 
cytosolic enzymatic processes or transported to the mitochondria where it is 
incorporated into heme-biosynthesis or packaged into Fe-S clusters.5 Excess Fe(II) is 
either oxidized and stored in ferritin or exported through ferroportin. 
The concentration of the LIP is regulated through stabilization or repression of mRNA 
through iron response proteins (IRPs) binding corresponding iron response elements 
(IREs) in the mRNA.6,7 IRPs sense if the concentration of free Fe(II) in the cytosol 
begins to fall outside the acceptable range (approx. 100 nM to 1 uM).3 In the case of low 
iron, IRP1 and IRP2 will bind 5’ IREs on ferritin and ferroportin, effectively silencing 
translation, while also binding 3’ IREs for transferrin receptor and DMT1 as a 
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mechanism for mRNA stabilization causing increased translation of these proteins. In 
the presence of high Fe(II), IRP2 is degraded entirely while IRP1 binds an Fe-S cluster 
precluding the active site from binding IREs. This allows ferritin and ferroportin mRNA to 
be translated while transferrin receptor and DMT1 mRNA is destabilized and is 
degraded. 
	
Figure 1-1: Figure adapted from Torti, S. & Torti, F. Nat Rev. Cancer. 2013, 13, 342-355. Iron 
metabolism is altered in cancer cells. While healthy cells will keep a tight regulation on the 
concentration of the labile iron pool (left), many cancers will alter nodes of iron metabolism to 
hoard excess iron and increase their LIP (right). Examples include an increased transferrin 
receptor expression and decreased ferroportin expression. 
 
Despite such a tight regulation in healthy cells, many cancers have been known to 
modulated basal expression of these otherwise highly-regulated protein in this iron 
metabolism pathway (Figure 1-1). For example, many pancreatic, lung, and prostate 
cancers are known to upregulate the expression of transferrin receptor while highly 
aggressive breast cancers have severely decreased expression of ferroportin.8–11 Most 
of these aberrant protein expression examples suggest an inverse correlation between 
a cancer patient’s prognosis and the tumor’s avidity for iron.12 While this increased iron 
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is potentially toxic to the cancer, it also allows the tumor to grow and proliferate more 
rapidly than otherwise normal tissues. 
Within the past few decades, there has been an increased effort in understanding and 
targeting this aberrant iron metabolism in the cancer patients. Extensive studies were 
performed in the 1990s attempting to utilize transferrin-drug conjugates to hijack the 
elevated transferrin receptor levels in cancers, though not with much success.13,14 More 
recently clinical trials have been performed dosing cancer patients with iron chelators, 
or molecules that sequester iron within the cell.15,16 The Renslo lab has utilized an 
Fe(II)-activated prodrug platform leveraging the reactivity of the 1,2,4-trioxolane scaffold 
(TRX) to selectively deliver bulk cytotoxins in preclinical xenograft models, however 
there is a lack of  diagnostic tools to determine Fe(II) levels in a spontaneous tumor.17,18  
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Chapter 2: Development of an Fe(II) reactive TRX-based PET imaging 
agent to detect reactive iron pools in vivo 
	
Despite ferrous iron playing such a crucial role in a variety of metabolic activities, and its 
dysregulation being implied in a multitude of diseases, there remains no method to 
measure variations in labile Fe(II) in vivo. This is due to a variety of factors, such as the 
difficulty in distinguishing between redox states, a lack of any reliable biomarkers, and 
the low concentration of ferrous iron. 
ABSTRACT 
Redox cycling of iron powers various enzyme functions crucial for life, making the study 
of iron acquisition, storage, and disposition in the whole organism a worthy topic of 
inquiry. However, despite its important role in biology and disease, imaging iron in 
animals with oxidation-state specificity remains an outstanding problem in biology and 
medicine. Here we report a first-generation reactivity-based probe of labile ferrous iron 
suitable for positron emission tomography studies in live animals. The responses of this 
reagent to systemic changes in labile iron disposition were revealed using iron 
supplementation and sequestration treatments in mice, while the potential of this 
approach for in vivo imaging of cancer was demonstrated using genetically and 
pathologically diverse mouse models, including spontaneous tumors arising in a 
genetically engineered model of prostate cancer driven by loss of PTEN. 
INTRODUCTION 
Iron is a transition metal nutrient whose redox cycling is utilized by iron-dependent 
enzymes to perform various biological functions essential to life.1,2 The storage, 
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transport, and utilization of iron is highly regulated in normal cells and tissues due to the 
potential of free ferrous iron to promote Fenton chemistry and the formation of reactive 
oxygen species. Accordingly, iron in biology is stored and transported in an inert ferric 
state, bound with high affinity by proteins including ferritin (storage) and transferrin 
(transport). Unloading of iron from transport and storage proteins involves reduction to 
the soluble ferrous state and entry into the cytosolic labile iron pool (LIP),3,4 from which 
iron is utilized to produce essential enzyme cofactors including iron heme1 and 
iron−sulfur clusters.5,6 Dysregulation of iron homeostasis occurs in diverse disease 
states significantly impacting public health, including neurodegenerative disease,7 
cardiovascular disease,8 inflammation,9 and cancer.10,11 Given its important role in 
biology and disease, the development of chemical reagents to detect iron with metal ion 
and oxidation-state specificity is an important problem in chemical biology.12,13 One of 
the earliest and most widely used probes, calcein AM, is a chelation-based reagent that 
unfortunately exhibits poor selectivity for Fe(II) over Fe(III) and other metal ions.14,15 
Improved metal and oxidation-state selectivity was later achieved in the first generation 
of reactivity-based iron probes, such as Rho-Nox116 and IP-1.17 Subsequently, Renslo 
and co-workers introduced the reactivity-based probe TRX-PURO,18 an iron-caged form 
of puromycin that is activated by Fe(II)-promoted fragmentation of a 1,2,4- trioxolane 
(TRX) moiety. Immunofluorescence imaging of TRX-PURO treated cells affords 
improved sensitivity18 compared to Rho-Nox1 and IP-1, but its use in mice requires the 
laborious ex vivo analysis of mouse tissues. Caged fluorescent probes are also 
unsuitable for in vivo studies due to the limited tissue penetration of short wavelength 
probes.19,20 Caging of D-aminoluciferin with the TRX moiety used in TRX-PURO 
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produced the iron probe ICL-1,21 which enables imaging of labile iron in live, luciferase-
expressing mice. Despite the advances described above, reactivity-based imaging of 
labile ferrous iron in nontransgenic animals and humans remains an outstanding 
problem in biology and medicine. We considered that this challenge might be met in 
Fe(II)-sensitive, TRX-based radiotracers for positron emission tomography (PET). 
Incorporation of positron-emitting radionuclides such as fluorine-18 or carbon-11 in 
biologically active small molecules generally has minimal pharmacological impact.22 
Moreover, PET is used widely in both 
basic science and clinical settings, 
affording 3-D noninvasive views of an 
experimental animal model or human 
patient.23 18F radionuclide is also widely 
available for routine preclinical and 
clinical use, and has a convenient 110 
min half-life that allows sufficient time 
for radiotracer preparation and imaging, 
while ensuring a relatively low radiation 
dose in patients.24 The degradation 
mechanism of 1,2,4-trioxolane 
antimalarials like artefenomel25 (Figure 
2-1A) has been widely studied, with 
Fe(II)-promoted cleavage of the 
peroxide bond and a subsequent β-
Figure 2-1 (A) Structure of artefenomel and 18F-TRX. 
(B) Reaction with Fe2+ yields 18F-TRX-linked 
biomolecule adducts that are sequestered in cells at 
site(s) of reaction. 
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scission reaction producing carbon-centered radicals that can be intercepted with stable 
radical reagents like TEMPO,26 or by nearby biological macromolecules when formed in 
cells.27 This radical trapping chemistry thus provides a mechanism by which a putative 
PET reagent would become sequestered in cells and tissues in an Fe(II)-dependent 
fashion. Accordingly, we designed the trioxolane-based reagent 18F-TRX in which a 
short linker bearing 18F is introduced on the adamantane moiety of artefenomel (Figure 
2-1A). The 4-fluorobenzamide function in 18F-TRX would be introduced in a final 
reaction step, using well-established N-succinimidyl-4-[18F]fluorobenzoate 
radiochemistry. We anticipated that 18F-TRX, like artefenomel, would be stable and well-
distributed in vivo, while reacting and becoming sequestered in those cells/ tissues 
where aberrant concentrations of labile ferrous iron are encountered (Figure 2-1B). 
Herein, we describe the synthesis of 18F-TRX, a first generation reactivity-based PET 
probe of labile ferrous iron. We show that this new scaffold retains Fe(II)-dependent 
reactivity in vitro and accumulates in cells in an Fe(II)- dependent fashion. We describe 
mouse pharmacokinetic and biodistribution studies in healthy mice with macro- and 
microdosing, where we observed relatively rapid elimination of 18F-TRX from the blood 
pool and significant radiotracer uptake in small intestine at 60 min post-injection. The 
iron sensitivity of 18F-TRX biodistribution in vivo was confirmed using iron 
supplementation and withholding strategies. Finally, we show enhanced accumulation 
of 18F-TRX in human and mouse tumors (up to ∼5% ID/g) compared to normal 
reference tissue compartments like blood and muscle. Overall, this study marks a first 
step toward a general method for sensitive and selective imaging of labile iron in living 
animals and suggests a new approach for functional imaging of cancer. 
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RESULTS AND DISCUSSION  
Radiosynthesis of 18F-TRX 
	
Scheme 2-1: Radiosynthesis of 18F-TRX 
 
The synthesis of 18F-TRX required the novel 1,2,4-trioxolane precursor reagent TRX-
amine in which an amine-bearing side chain has been introduced at a bridgehead 
position on the adamantane ring (Scheme 2-1). This reagent was synthesized in eight 
steps, based on the general approach described for the synthesis of artefenomel25 and 
related antimalarial trioxolanes. The radiosynthesis of 18F-TRX began with the 
automated preparation of 18F-N-succinimidyl 4-fluorobenzoate. Using an ELIXYS 
automated radiosynthesizer, 18F-SFB was prepared in 75 min to a decay-corrected 
radiochemical yield of approximately 70%.28,29 For the coupling reaction, 20 mCi of 18F-
SFB was added to TRX-amine (5 mg of a formate salt) and 10% (v/v) DIPEA in 
anhydrous DMF (1 mL). The reaction was stirred at 40 °C for 30 min. The reaction 
produced only one major radioactive peak, which comigrated with the 19FTRX standard 
(Figure 2-2A). The crude reaction was purified using semipreparative HPLC (1:10  
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Figure 2-2: Synthesis and isolation of 18F-TRX. (A) Representative semipreparative rad-HPLC 
traces showing, from top, the UV spectrum at 254 nm for TRX-amine starting material, the UV 
spectrum at 254 nm for the pure 19F-TRX analytical standard, the UV spectrum at 254 nm for 
complex radiochemistry reaction mixture at 40 min, and the rad spectrum of the complex 
radiochemistry reaction mixture at 40 min. Peaks of interest are labeled with the retention time in 
minutes. (B) Semipreparative rad-HPLC traces of the reinjected fraction isolated after purification. 
The retention time in minutes of the peak of interest representing 18F-TRX is labeled. (C) A rad 
spectrum collected 30 min after incubation of 18F-TRX in aqueous ammonium Fe(II) sulfate (30 
mg/mL) showing disappearance of the peak corresponding to 18F-TRX and appearance of a new 
peak with a different retention time. 
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CH3CN:H2O to 19:1 CH3CN:H2O over 20 min) to obtain the radiotracer 18F-TRX to a 
decay-corrected radiochemical yield of 67 ± 7.2%. The purity of the compound was 
verified by reinjection on semiprep HPLC (Figure 2-2B). 18F-TRX was concentrated, 
and immediately reconstituted for additional in vitro or animal studies. The specific 
activity of 18F-TRX was calculated to be 0.052 ± 0.02 Ci/µmol.  
In Vitro Studies Show That TRX Analogues React with Fe(II) and Cross-Link 
Cellular Proteins  
To confirm that 18F-TRX retains reactivity with Fe(II), the purified compound was 
exposed to aqueous ammonium Fe(II) sulfate (FAS, 30 mg/mL). After 30 min, 18F-TRX 
was entirely consumed and cleanly converted to a single radioactive byproduct as 
observed on reverse phase rad-HPLC (Figure 2-2C). This result indicates that the 
reactivity of 18F-TRX with Fe(II) is highly regioselective, as was expected based on 
earlier mechanistic studies26 of the antimalarial compounds on which 18F-TRX is based. 
To confirm that the 18F-bearing side chain in 18F-TRX becomes sequestered in cells 
following reaction with Fe(II), we prepared the nonradioactive “clickable” probe HC2-
TRX (Figure 2-3A) in which an alkyne function replaces the fluorine atom in 18F-TRX. 
Fluorescence cell imaging of PC3 cells treated with HC2-TRX followed by fixing and 
copper(I)- catalyzed alkyne−azide cycloaddition (CuAAC) reaction with Alexa488-azide 
were consistent with irreversible labeling of cytoplasmic targets (Figure 2-3B). An in-gel 
TAMRA fluorescence analysis confirmed the promiscuous labeling of proteins in PC3 
cells treated with HC2-TRX (Figure 2-3C). Moreover, pretreating PC3 cells with ferric 
ammonium citrate (FAC) or the iron chelator desferrioxamine (DFO) prior to HC2-TRX 
revealed more and less labeling, respectively, consistent with iron-dependent activation.  
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Figure 2-3 Cellular probe HC2-TRX promiscuously labels proteins in PC3 cells. (A) Structure of 
cellular “clickable” probe HC2-TRX. (B) Representative fluorescence images of PC3 cells treated 
with HC2-TRX for 6h and visualized by CuACC reaction with Alexa488-azide (green, FITC 
channel); cell nuclei are visible in the DAPI channel (blue). Scale bars denote 50 µm. (C) In-gel 
TAMRA fluorescence analysis reveals promiscuous protein labeling following incubation of PC3 
cells with HC2-TRX. Enhanced labeling is observed when PC3 cells were pretreated (2 h) with 
the Fe(III) source FAC (500 µM) before treatment with HC2-TRX. Conversely, PC3 cells 
pretreated with the iron chelator DFO (300 µM) showed reduced labeling intensity. Coomassie 
(Coo) staining is used as a loading control. 
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These findings with HC2-TRX indicate that the analogously positioned 18F atom in 18F-
TRX would similarly become sequestered in cells in an Fe(II)-dependent fashion. 
18F-TRX Biodistribution Is Fe(II)-Dependent in Normal Mouse Tissues 
To determine the biodistribution of 18F-TRX in clinically relevant mouse models, the 
radiotracer was injected into immunocompetent C57Bl/6J mice and studied over time. 
Region of interest analysis of a dynamic PET/CT acquisition from 0 to 60 min 
postinjection revealed several enlightening trends. First, 18F-TRX rapidly cleared from 
the mediastinal blood pool at a rate ∼60 times faster than what we observed from a 
classic PK assessment of 19F-TRX (Figure 2-4A). Moreover, 18F-TRX rapidly 
accumulated in liver from 0 to 60 s, suggesting that the radiotracer may be metabolized 
and cleared through this organ (Figure 2-4B,C) as is the case for artefenomel in 
humans.30 Kidney accumulation of the radiotracer was also observed, but the uptake 
was significantly lower than liver. Moreover, kidney uptake plateaued within 30 s 
postinjection, suggesting that (as with artefenomel) renal clearance is not the dominant 
mechanism of clearance of radiotracer. Focal uptake in a region of the small intestine 
was also observed early after radiotracer injection, and the accumulation steadily 
increased from 400 to 3600 s. This observation is also consistent with a model of 
hepatobiliary excretion. To study radiotracer distribution over a broader window of time, 
ex vivo biodistribution studies were conducted at 30, 60, and 90 min postinjection of 18F-
TRX in a separate cohort of mice (Figure 2-4D). These studies generally corroborated 
the PET findings, showing that 18F-TRX uptake was dominant in the liver, components 
of the small intestine, and the kidneys. Moreover, radiotracer uptake generally 
increased from 30 to 90 min in these tissues. Radiotracer uptake was also observed in  
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Figure 2-4 An in vivo assessment of the biodistribution of 18F-TRX in tumor naïve 
immunocompetent mice. (A) Plasma concentration–time curve for 19F-TRX administered via tail 
vein injection in C57Bl/6J mice revealing a plasma half-life of ∼30 min. (B) Time activity curves 
derived from region of interest analysis of a 1 h dynamic PET scan reveal radiotracer 
biodistribution in vivo. The radiotracer rapidly clears from the blood (red) with a calculated 
serum half-life of about 25 s. The radiotracer is also sequestered within 60 s by the liver (tan) 
and kidneys (blue), with no additional accumulation from 60 to 3600 s. Liver uptake is 
significantly higher than what is observed in kidneys. Also, 18F-TRX accumulation in the small 
intestine (gray) steadily increases from 0 to 3600 s, consistent with a model of hepatobiliary 
clearance for the radiotracer. Little uptake is observed in the muscle (green). Figure S2C shows 
the location of the manually drawn regions of interest. (C) Maximum intensity projections 
sampled serially over short time frames from the dynamic acquisition show the biodistribution of 
the radiotracer in normal tissues over time. A diffuse signal is observed at early time points, 
which gradually consolidates into the liver, kidney, and small intestine. (D) Biodistribution data 
acquired at 30, 60, and 90 min postinjection of 18F-TRX show continuous accumulation of the 
radiotracer in many abdominal organs. The highest uptake was observed in the liver, kidneys, 
and small intestine. Radiotracer accumulation was low in the blood pool and muscle, as 
expected from the MIPs. (E) A PET/CT shows the biodistribution of 18F-TRX in components of 
the gastrointestinal tract after dissection from a mouse. Prominent uptake was observed in the 
duodenum and jejunum, while comparatively lower radiotracer uptake was noted in the 
stomach, ileum, cecum, and large intestine. Liver, kidneys, and muscle are included for 
perspective on the upper and lower bound of radiotracer uptake in tissues. 
 
the spleen, pancreas, stomach, large intestine, and lungs. Uptake in the brain was very 
low, consistent with previous observations that other TRX conjugates do not cross the 
blood−brain barrier.31 To better understand the localization of the radiotracer within 
regions of the small intestine, components of the GI tract were excised from a 
representative mouse 60 min postinjection, and radiotracer biodistribution was 
assessed with PET/CT (Figure 2-4E). This study suggested that radiotracer uptake was 
predominant in the duodenum and jejunum. Comparatively lower uptake was observed 
in the ileum, cecum, and a truncated segment of the large intestine (purged manually to 
remove fecal matter). 
We next tested whether 18F-TRX biodistribution was impacted by exogenous treatments 
designed to alter tissue concentrations of ferrous iron. 20 minutes prior to i.v. injection of 
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18F-TRX, immunocompetent mice were treated with an i.p. bolus of PBS, ferric 
ammonium citrate (FAC, 20 mg/kg), desferrioxamine (50 mg/kg, DFO), deferiprone (50 
mg/kg, DFP), or a mixture of FAC (20 mg/kg) precomplexed with desferrioxamine (50 
mg/kg, FAC + DFO). The use of a ferric iron source ensures that bioconversion to 
ferrous iron by normal cellular processes is a necessary prelude to reaction with 18F-
TRX. The biodistribution of the radiotracer at 60 min postinjection was strikingly different 
between treatment arms on PET/CT (Figure 2-5A). For instance, while 18F-TRX most 
visibly accumulated in the liver of mice treated with PBS, FAC treatment elevated 
uptake in the liver, small intestine, and gall bladder. Iron depleting strategies (e.g., DFO, 
FAC + DFO, DFP) reduced radiotracer uptake in the liver, while clearly redistributing 
18F-TRX to components of the small intestine. Quantitative biodistribution studies 
showed a statistically significant increase in 18F-TRX uptake in the liver, spleen, 
pancreas, and duodenum of mice treated with FAC versus those treated with PBS 
(Figure 2-5B). 
Moreover, treatment with iron chelating agents significantly reduced 18F-TRX uptake in 
virtually all tissues, with the notable exceptions of the duodenum, ileum, cecum, and 
large intestine in the FAC + DFO treatment arm. In summary, these data demonstrate 
that 18F-TRX biodistribution is substantially influenced by exogenous treatments 
designed to modulate tissue concentrations of ferrous iron. 18F-TRX Detects Tumor 
Xenografts Sensitive to Trioxolane Prodrugs. We next evaluated if 18F-TRX can detect 
human tumors derived from cell lines previously shown to harbor sensitivity to TRX-
based iron(II)-activatable prodrugs.32 Biodistribution studies were first conducted in 
intact male nu/nu mice bearing subcutaneous PC3 xenografts at 30, 60, and 90 min 
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postinjection of 18F-TRX. The uptake of the radiotracer steadily increased from 30 to 90 
min postinjection. Radiotracer levels in the tumor significantly exceeded blood and 
muscle at 90 min postinjection with a tumor to blood ratio of 1.97 ± 0.4 and a tumor to 
muscle ratio of 1.90 ± 0.3 (Figure 2-6A). We further tested if 18F-TRX can detect PC3 
tumors implanted in the renal capsule, which provides a better vascularized  
	
Figure 2-5 18F-TRX biodistribution is substantially altered by exogenous treatments that change 
intracellular iron homeostasis. (A) (top) A timeline outlining the sequence of injections in 
immunocompetent C57Bl/6J mice prior to PET/CT and biodistribution studies. (bottom) 
Representative maximum intensity projections (MIPs) showing the biodistribution of 18F-TRX in 
mice from each treatment arm from 50 to 60 min postinjection. Radiotracer uptake was 
predominantly in the liver of mice pretreated with PBS, while pretreatment with ferric ammonium 
citrate (FAC) augmented radiotracer uptake in nearly all organs, including the liver and 
components of the gastrointestinal tract. Pretreatment with various iron depleting agents, 
including desferrioxamine (DFO), FAC complexed with DFO, and deferiprone (DFP), generally 
reduced radiotracer uptake in organs and accelerated clearance. The MIPs, while inherently 
semiquantitative, were derived from decay-corrected PET data with scale bars adjusted to the 
range 0–50% ID/g to enable gross comparison. (B) Biodistribution data collected at 60 min 
postinjection show the percent changes in radiotracer uptake for selected organs in each 
treatment arm compared to mice receiving PBS. Relative increases in radiotracer uptake due to 
FAC treatment were observed in nearly all organs, while iron depleting treatments generally 
reduced organ uptake of the radiotracer. Treatment with FAC + DFO enhanced radiotracer 
uptake in components of the gastrointestinal tract, which may reflect accelerated clearance of 
the radiotracer. 
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environment than subcutaneous implants. Biodistribution studies conducted 90 min 
postinjection of 18F-TRX showed equivalent radiotracer uptake in a PC3 tumor 
embedded in the renal capsule compared to the extent of uptake in subcutaneous PC3 
tumors (Figure 2-6B). 18F-TRX uptake was also significantly higher than background 
(blood and muscle) in subcutaneous EKVX and U251 tumors, two models of human 
lung adenocarcinoma and glioblastoma, respectively (Figure 2-6B). The U251 tumor, 
the model with the highest 18F-TRX uptake, was visually obvious on small animal 
PET/CT (Figure 2-6C). Ex vivo analysis of the spatial distribution of the radiotracer in 
U251 tumors showed that 18F-TRX was well-distributed through the tumor xenograft, 
with the regions of highest uptake appearing to have the densest cellularity on H&E 
(Figure 2-6D). Collectively, these data show that genetically and pathologically diverse 
models of human cancer harbor high avidity for 18F-TRX in vivo. We next conducted a 
pilot imaging study in a genetically engineered mouse model of prostate cancer.33 A 10 
month old Pb-Cre:Ptenfl/fl mouse with invasive adenocarcinoma was treated with 18F-
TRX, and after 90 min, the whole prostate was resected post mortem and imaged with 
PET/CT. Radiotracer uptake was visually higher in the prostate tissue compared to 
seminal vesicles and muscle (Figure 2-6E). Moreover, 18F-TRX uptake was 
predominant in the prostate tissue, and not observed in the cysts that routinely develop 
in this disease model.  
		 20	
	
Figure 2-6 18F-TRX detects tumor tissue in vivo in genetically and pathologically diverse cancer 
models. (A) Biodistribution data acquired at 30, 60, and 90 min postinjection of 18F-TRX in male 
nu/nu mice with subcutaneous PC3 xenografts. The radiotracer uptake in the tumor continually 
increases from 30 to 90 min, consistent with a reactivity-based mechanism of action. Moreover, 
radiotracer uptake in the tumor exceeds the level observed in blood and muscle at 90 min 
postinjection, two standard reference compartments for background radiotracer accumulation. 
The human prostate cancer model PC3 was prioritized as it was previously shown to be highly 
sensitive to an Fe(II)-sensitive TRX prodrug bearing a chemotherapeutic payload.(32) *P < 0.01 
compared to blood and muscle. Figure S4 shows the biodistribution values for the entire 
repertoire of tissues from this animal cohort as well as the tumor to normal tissue ratios. (B) 
Biodistribution data acquired 90 min postinjection of 18F-TRX shows radiotracer uptake in tumor 
exceeding background for PC3 tumors implanted in the renal capsule (rcPC3), and 
subcutaneous EKVX and U251 tumors (scEKVX, scU251). Figure S5 shows a MR image 
highlighting the tumor burden in renal capsule. Figure S6 shows the complete biodistribution 
data sets, and the tumor to normal tissue ratios. (C) PET/CT imaging data showing uptake 
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of 18F-TRX in tumor and normal tissues for mice bearing subcutaneous U251 tumors. The data 
were acquired at 90 min postinjection. (D) H&E (left) and digital autoradiography (right) 
showing 18F-TRX distribution within a representative section of U251 tumors. 18F-TRX appears 
to be present in all regions of the slice, with the highest relative uptake appearing to colocalize 
with the area of densest cellularity on H&E. (E) (left) A photograph of the surgically excised 
whole prostate (Pr.), a piece of muscle from the hindlimb (Mu.), and the seminal vesicles (SV) of 
a 10 month old Pb-Cre:Ptenfl/fl mouse with fully invasive adenocarcinoma. Cysts extending from 
the anterior prostate are evident by eye. (middle) A volume rendered CT image of the tissues 
acquired on a small animal PET/CT. (right) A volume rendered PET/CT image of 18F-TRX 
uptake in the tissues acquired 90 min postinjection of 18F-TRX. The image clearly shows 
relatively higher accumulation of radiotracer in the diseased prostate compared to muscle or 
seminal vesicles. 18F-TRX was excluded from the cysts, as expected. 
 
CONCLUSION  
Here we reported the design, synthesis, and characterization of 18F-TRX, a reactivity-
based PET radiotracer that enables quantitative imaging of labile Fe2+ in living animals, 
including its application to several clinically relevant human and mouse cancer models. 
Based on an antimalarial with Fe(II)-dependent pharmacology, 18F-TRX can react with 
Fe2+ and become sequestered in tissues at the site(s) of its Fe(II)-promoted activation in 
vivo. Biodistribution studies and ex vivo imaging revealed high levels of radiotracer 
uptake in liver and small intestine that could be altered by pretreatment with bioavailable 
iron sources (FAC) or iron chelators (DFO). Furthermore, 18F-TRX was capable of 
detecting elevated Fe2+ levels in tumor compared to blood pool and muscle in PC3, 
EKVX, and U251 xenograft models and in a genetic prostate cancer model. These 
results suggest that labile Fe2+ represents an actionable analyte for cancer imaging with 
PET in animals.  
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MATERIALS AND METHODS 
Radiosynthesis of 18F-TRX  
18F-SFB was prepared in 75 min to a decay-corrected radiochemical yield of 
approximately 70%. 18F-SFB was transferred from the ELIXYS on a C18 SepPak 
cartridge, and the 18F-SFB was eluted from the cartridge using neat CH3CN. The 
acetonitrile was removed under vacuum and a gentle stream of N2(g), and to the 18F-
SFB (20 mCi) was added TRX-amine (5 mg, as formate salt) and 10% (v/v) DIPEA in 
anhydrous DMF (1 mL). The reaction was stirred at 40 °C. Reaction progress was 
monitored by radHPLC, and the reaction was terminated at 30 min, as the coupling of 
19F-SFB to TRX-amine under analogous conditions was complete at 30 min. The crude 
reaction was purified using semipreparative HPLC (1:10 CH3CN:H2O to 19:1 
CH3CN:H2O over 20 min) to obtain the radiotracer 18F-TRX to a decay-corrected 
radiochemical yield of 67 ± 7.2%. The purity of the compound was verified by reinjection 
on semiprep HPLC.  
Cell Culture and Cell/Protein Labeling Experiments 
The PC3, EKVC, and U251 cell lines were obtained from ATCC (Manassas, VA) and 
cultured in Dulbecco’s modified Eagle’s medium (VWR) supplemented with 10% fetal 
bovine serum (Gemini Bio) and 1× penicillin/streptomycin (Life Technologies). Cells 
were cultured at 37 °C supplemented with 5% CO2. For the fluorescence cell imaging 
experiment, PC3 cells were cultured in a 96-well Greiner µClear plate until reaching 
75% confluence. Media was removed and replaced with media containing trioxolane 
HC2-TRX (20 µM, 0.1% DMSO) or vehicle (0.1% DMSO). After 6 h, cells were washed 
		 23	
with PBS twice and then fixed with 4% paraformaldehyde for 10 min at room 
temperature (rt). Cells were washed with PBS twice and incubated with PBS 
supplemented with 0.1% Triton X-100 for 5 min. Cell were then washed with PBS three 
times, then incubated for 1 h with click master mix (5 mM sodium ascorbate, 2 mM 
THPTA, 500 µM CuSO4, 10 µM Alexa488- azide), and then washed with PBS three 
times. Cells were then treated with PBS containing Hoechst nuclear stain for 10 min, 
washed with PBS twice, and imaged with an IN Cell 6500 automated cell imager at 40× 
magnification. For the protein labeling and in-gel fluorescence experiment, PC3 cells 
were cultured in 6-well plates until reaching 75% confluence. Media was then removed 
and replaced with fresh media or fresh media containing FAC (500 µM) or DFO (300 
µM). After 2 h, media was removed and replaced with media containing HC2-TRX (20 
µM, 0.1% DMSO) or vehicle (0.1% DMSO). After 6 h, cells were washed with PBS twice 
then incubated in cold PBS for 5 min. Cells were collected using a plastic cell scraper 
and pelleted. The pellet was resuspended in 100 µL of cold 0.1% NP40 lysis buffer (100 
mM Hepes, 150 mM NaCl, 0.1% NP40, pH 7.5) with 5 mg/mL EDTA free protease 
inhibitor (Roche) for 30 min on ice. The following lysate was centrifuged at 13000 rpm 
for 10 min. Protein concentration was determined using Pierce BCA protein assay kit 
(Thermo Fisher) and subsequently normalized to 1 mg/ mL. To 50 µL of this lysate was 
added the click reaction cocktail (final concentrations: 25 µM TAMRA-Azide, 1 mM 
CuSO4, 0.1 mM TBTA, 1 mM TCEP), and it was incubated at room temperature for 1 h 
in the dark. Protein was precipitated by addition of 1 mL of cold methanol and cooled to 
−80 °C. Protein was pelleted by centrifugation at 14000 rpm for 5 min at 4 °C. Methanol 
was decanted, and the protein pellet was washed with 1 mL of cold methanol and 
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pelleted again as described. Methanol was decanted, and the pellet was resuspended 
in 50 µL of 1× laemmli buffer (Bio-Rad) supplemented with β-mercaptoethanol. Sample 
was boiled for 5 min, and 25 µg of protein was loaded onto Bolt 4−12% Bis-Tris Plus 
Gel (Thermo Fisher). Fluorescence was visualized by a ChemiDoc system and 
displayed in a grayscale. Following imaging, total protein was visualized by Coomassie 
stain.  
Animal Experiments 
To reconstitute 18F-TRX for animal studies, the probe was trapped on a C18 Sep-Pak 
cartridge, and eluted with a small volume of ethanol. Ethanol was removed at 50 °C 
under vacuum and a gentle stream of N2 (g) to afford neat 18F-TRX. Formulation of 18F-
TRX for in vivo studies proved challenging due to the very poor aqueous solubility of 
this material. After some experimentation, we adopted a formulation comprising 10% 
DMSO in a 20 mM aqueous sodium phosphate solution at pH 3 used previously by 
Charman and co-workers25 for IV pharmacokinetic studies of artefenomel. A 5 mg/kg 
dose of 19F-TRX in 100 µL of this formulation was well-tolerated in mice when 
administered by tail vein injection. All animal experiments were conducted under the 
approval from Institutional Animal Care and Use Committee (IACUC) at UCSF. Male 
nu/nu or C57BL6/J mice (4−6 weeks) were purchased from Charles River. All the mice 
were well-housed in the USCF with free access to food and water. Nu/nu mice were 
inoculated with 2−5 x 106 PC3 cells in a mixture of media (RPMI) and Matrigel (Corning) 
(1:1 v/v) subcutaneously into one flank. Tumors in mice were palpable within 3−4 weeks 
after the implanting. Male Rag2 RAGN12 mice (Taconic) were used for the renal 
capsule tumor implants. The mice were anesthetized with isofluorane (2−3%) and 
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performed with a dorsal midline incision (0.5 cm). Via pressuring on the muscle wall, 
one kidney was pulled gently and carefully through the small incision. PC3 tumor cells 
(5 × 106 in 50 mL of PBS) were then injected into the pocket under the kidney capsule, 
which was lifted from the kidney parenchyma. The kidney was placed back to the body 
of mice, and then the skin incision was closed using 3 surgical sutures. Carprofen (5−10 
mg/kg) was used to treat the mice for easing recovery. Mice were observed carefully 
over 24 h for the signs of postoperative bleeding, pain, and (or) other complications. 
After surgery, a 14 T Agilent small animal MRI was used to monitor the tumor 
progression for the following 7−14 days. Small Animal PET/CT. 18F-TRX (∼300 µCi) 
was injected via tail vein in 100−150 µL of 10% DMSO in a 20 mM aqueous sodium 
phosphate solution. For treatment studies, vehicle (100 µL PBS), FAC (20 mg/kg in 
PBS, 100 µL), both FAC (20 mg/kg in PBS, 100 µL) and DFO (50 mg/kg in PBS, 100 
µL), DFP (30 mg/kg in PBS, 100 µL), or DFO (30 mg/kg in PBS, 100 µL) were injected 
intraperitoneally 20 min prior to the intravenous injection of 18F-TRX. The mice were 
anesthetized with 2−3% isoflurane, and imaged with a Siemens Inveon microPET/CT. 
For dynamic acquisitions, the mice were anesthetized prior to injection, and injected 
while positioned on the scanner bed. All imaging data were decay-corrected, 
reconstructed, and analyzed with AMIDE software. Maximum intensity projections 
(MIPs) were generated by AMIDE software. Regions of interest (ROI) were manually 
placed to calculate SUV data from the dynamic acquisitions. Biodistribution Studies. 
Mice were euthanized with CO2 (g) asphyxiation and dissected at dedicated time points 
postinjection. The blood and tissues were removed, washed, dried, and weighed. The 
activity of each tissue was measured with a γ counter. All data were decay-corrected. 
		 26	
PRISM software was used to express a percentage (% ID/g) of the injected dose per 
gram of tissue. Digital Autoradiography. Postmortem, tumors were flash frozen in OCT 
on liquid nitrogen. The tissue was sectioned with a microtome into 20 µm thickness 
slices and mounted on glass slides. The slides were exposed in a GE phosphor storage 
screen for 10 radionuclide half-lives. The phosphor screen was developed on an 
Amersham Typhoon 9400 phosphorimager. The images were processed using ImageJ 
software. H&E staining was performed by the Pathology core facility at UCSF. Statistics. 
All statistical analysis was performed using PRISM v6.0 or ORIGIN software. An 
unpaired, two-tailed Student’s t test was used to determine statistically significant 
differences in the data. Changes at the 95% confidence level (P < 0.05) were reported 
as statistically significant.  
 
SUPPORTING INFORMATION 
	
Scheme S2-1: Synthesis of adamantane oxime 2 
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Synthesis of methyl 4-oxoadamantane-1-carboxylate (1). To a round bottom flask 
containing a Teflon-coated magnetic stir bar under an Ar(g) atmosphere was added 4-
oxoadamantane-1carboxylic acid (3.885 g, 20.0 mmol, 1.0 equiv.), HATU (9.219 g, 24.0 
mmol, 1.2 equiv.), N,Ndimethylformamide (80 mL), methanol (8.103 ml, 200.0 mmol, 
10.0 equiv.), and 4dimethylaminopyridine (1.222 g, 10.0 mmol, 0.5 equiv.). After 
addition of the HATU, the solution turned a dark orange color. The solution was allowed 
to at room temperature for 16 hours. Based on TLC and LCMS analysis, the reaction 
was complete. To this reaction was added DI Water (75 mL). The aqueous layer was 
then extracted with ethyl acetate (3 x 75 mL). The organic layers were collected and 
washed with brine (3 x 75 mL) to remove excess DMF. The organic layer was dried over 
magnesium sulfate and filtered under vacuum. Organic solvent was removed under 
reduced pressure to give a dark brown solution in residual DMF. This crude product was 
purified through flash column chromatography (330 g HP silica gel cartridge, 0– 20% 
EtOAc/Hexanes, product eluted during 20% EtOAc/Hex) to yield methyl 4-
oxoadamantane-1-carboxylate (1, 3.869 g, 93%) as a white, crunchy solid. 1H NMR 
signals were consistent with reported values.34   
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Synthesis of methyl-4-(methoxyimino)adamantane-1-carboxylate (2). To a sealed 
tube containing a Teflon-coated magnetic stir bar under an Ar(g) atmosphere was 
added methyl 4oxoadamantane-1-carboxylate (1, 3.800 g, 18.2 mmol, 1.0 equiv.) and 
methanol (36 mL). This solution was stirred until all solid had dissolved, then pyridine 
(2.946 ml, 36.5 mmol, 2.0 equiv.) and methoxylamine HCl (1.711 g, 20.1 mmol, 1.1 
equiv.) were added sequentially. The solution was again stirred at room temperature 
under argon until all of the solid went into solution. The reaction was played in an oil 
bath that had been preheated to 90°C and stirred for 4 hours. The solution was allowed 
to cool at which point TLC and LCMS analysis showed the reaction to be complete. The 
mixture was concentrated under reduced to give a white slurry. Following the addition of 
EtOAc (50 mL) and DI water (50 mL), the organic layer was collected and washed with 
KHSO4 (2 x 50 mL) and brine (1 x 50 mL). The organic layer was dried over MgSO4 and 
filtered. The mixture was concentrated under reduced to afford methyl-
4(methoxyimino)adamantane-1-carboxylate (2) as a white fluffy powder (4.186g, 97%). 
1H NMR signals were consistent with reported values.34   
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Scheme S2-2. Synthesis of TRX-amine and 19F-TRX  
 
 
Synthesis of methyl-4''-(4-acetoxyphenyl)dispiro[adamantane-2,3'-
[1,2,4]trioxolane-5',1''cyclohexane]-5-carboxylate (4). To a round bottom flask 
containing a Teflon-coated magnetic stir bar open to the atmosphere was added methyl-
4-(methoxyimino)adamantane-1-carboxylate (2,1.277 g, 5.4 mmol, 1.0 equiv.) and 4-(4-
acetoxyphenyl)cyclohexan-1-one (3, 1.250 g, 5.4 mmol, 1.0 equiv.). To the mixture of 
solid materials was added carbon tetrachloride (100 mL) and dichloromethane (5 mL). 
This solution was cooled to 0˚C and subsequently sparged with O2 for 10 minutes. The 
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reaction was kept at 0 ˚C while ozone was then bubbled (2 L/min, 35% power). Over the 
following 3 hours, an additional 0.5 equivalents of oxime was added until the reaction 
was determined to be complete. The reaction was purged with O2 for 10 minutes in an 
effort to remove any dissolved ozone, followed by sparging with argon gas for 10 
minutes to remove any dissolved oxygen. The reaction mixture was concentrated under 
reduced pressure to give a white slurry. This crude mixture was purified through flash 
column chromatography (0– 10% EtOAc/Hexanes) to yield methyl-4''-(4-
acetoxyphenyl)dispiro[adamantane-2,3'[1,2,4]trioxolane-5',1''-cyclohexane]-5-
carboxylate (4, 1.68 g, 69%) as an off-white foam. Analysis by LCMS and NMR 
indicates a mixture of diasteromers (ca. 8:1). 1H NMR (400 MHz, CDCl3) δ 7.25 (d, 8 
Hz, 2H, minor diastereomer), 7.21 (d, 8 Hz, 2H, major), 7.05-6.97 (m, 2H), 3.70-3.65 (m, 
3H), 2.62-2.51 (m, 1H), 2.29 (s, 3H), 2.26–2.19 (m, 2H), 2.17–1.79 (m, 16H), 1.77–1.64 
(m, 4H); 13C NMR (100 MHz, CDCl3) δ 177.1, 176.1 (minor diastereomer), 169.5, 148.8, 
143.4, 127.6, 121.3, 110.1, 108.5, 51.9, 51.6 (minor diastereomer), 42.2, 40.2, 40.0, 
39.8, 39.4, 38.2, 38.0 (minor diastereomer), 37.7, 36.2, 36.1 (minor diastereomer), 35.9, 
35.8 (minor diastereomer), 34.5, 33.6, 31.3, 27.2, 26.5, 26.1, 24.6, 21.0.; MS (ESI) 
calculated for C26H32O7 [M + Na]+ m/z 479.20, found 479.08.   
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Synthesis of 4''-(4-hydroxyphenyl)dispiro[adamantane-2,3'-[1,2,4]trioxolane-
5',1''cyclohexane]-5-carboxylic acid (5). To a round bottom flask containing a Teflon-
coated magnetic stir bar open to the atmosphere was added methyl-4''-(4- 
acetoxyphenyl)dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1''-cyclohexane]-5-
carboxylate (4, 1.685 g, 3.7 mmol, 1.0 equiv.) dissolved in anhydrous tetrahydrofuran 
(40 mL) and methanol (40 mL). To this stirring solution was 1M lithium hydroxide in 
water (14.8 ml, 14.8 mmol, 4.0 equiv.). The reaction was placed into an oil bath that had 
been preheated to 40˚C and was allowed to stir for 40 hours under argon at which point 
the reaction was determined to be complete. The reaction was concentrated under 
reduced pressure to give a white slurry. DI water (75 mL) and EtOAc (75 mL) were 
added to the crude mixture and transferred to an Erlenmeyer flask containing a Teflon-
coated magnetic stir bar and cooled to 0˚C. The pH of this stirring mixture was adjusted 
to 1 by dropwise addition of 1N HCl. The organic layer was collected and the aqueous 
layer was extracted with EtOAc (2 x 75 mL). The organic layers were combined and 
washed with brine (1 x 50mL). The organic layer was concentrated under reduced 
pressure to yield 4''-(4-hydroxyphenyl)dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1''-
cyclohexane]-5-carboxylic acid (5, 1.4g, 95%) as a white powder. 1H NMR (400 MHz, 
DMSO-d6) δ 12.18 (br s, 1H), 7.21 (br s, 1H), 7.05-6.96 (m, 2H), 6.71-6.64 (m, 2H), 
2.50-2.40 (m, 1H), 2.14–1.97 (m, 5H), 2.17–1.79 (m, 14H), 1.58–1.43 (m, 2H); 13C NMR 
(100 MHz, DMSO-d6) δ 177.6, 176.9 (minor diastereomer), 155.5, 136.1 127.4 (minor 
diastereomer), 127.3 115.0, 109.7, 108.4, 45.3, 40.7, 39.7, 38.8, 38.4, 37.7, 37.6 (minor 
diastereomer), 37.5, 37.3, 36.0, 35.9 (minor diastereomer), 35.5, 35.4 (minor 
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diastereomer), 34.1, 33.2, 31.4, 26.8, 26.0, 25.6; MS (ESI) calculated for C23H28O6 [M - 
H]- m/z 399.18, found 399.23.   
 
Synthesis of 4''-(4-(2-morpholinoethoxy)phenyl)dispiro[adamantane-2,3'-
[1,2,4]trioxolane5',1''-cyclohexane]-5-carboxylic acid (6). To a round bottom flask 
containing a Teflon-coated magnetic stir bar under Ar(g) was added 4''-(4-
hydroxyphenyl) dispiro[adamantane-2,3'[1,2,4]trioxolane-5',1''-cyclohexane]-5-carboxylic 
acid (5, 1.400 g, 3.5 mmol, 1.0 equiv.), 1M sodium hydroxide (31.5 ml, 31.5 mmol, 9.0 
equiv.) and tetrabutylammonium bisulfate (0.237 g, 0.7 mmol, 0.2 equiv.). This mixture 
was allowed to stir for 30 minutes at room temperature under argon, at which point 4-(2-
chloroethyl)morpholine hydrochloride (1.301 g, 7.0 mmol, 2.0 equiv.) was added. The 
reaction was placed into an oil bath that had been preheated to 50˚C. Over the following 
36 hours, an additional 3 equivalents of morpholine and sodium hydroxide were added 
starting material was no longer observed by LCMS. 1M NaOH (21 mL, 21 mmol, 6 eq) 
was then added in one portion and the reaction was allowed to stir at 50˚C for 4 hrs. At 
this point the reaction was determined to be complete by LCMS and the solution was 
concentrated under reduced vacuum to give a white slurry. To this crude mixture was 
added deionized water (75 mL) and EtOAc (75 mL). Following the addition of EtOAc, it 
was noted that a white precipitate had formed. This solid was filtered to give the product 
4''-(4-(2morpholinoethoxy)phenyl)dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1''-
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cyclohexane]-5carboxylic acid (6, 880 mg, 1.71 mmol, 49%) as a white powder. 1H NMR 
(400 MHz, CDCl3) δ 8.60 (br s, 1H), 7.18-7.09 (m, 2H), 6.88-6.80 (m, 2H), 4.16-4.08 (m, 
2H), 3.80-3.71 (m, 4H), 2.85 (t, 5.2 Hz, 2H), 2.72-2.63 (m, 4H), 2.54-2.45 (m, 1H), 2.27-
2.17 (m, 2H), 2.14–1.78 (m, 15H), 1.77–1.63 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 
181.3, 181.0 (minor diastereomer), 156.9, 138.6, 127.7, 114.5, 110.3, 108.7, 66.4, 66.3 
(minor diastereomer), 65.1, 65.0 (minor diastereomer), 57.4, 53.7, 53.6 (minor 
diastereomer), 42.1, 42.0, 41.4, 39.7, 39.2, 38.1, 38.0, 36.3, 36.1, 35.9, 34.7, 34.6 
(minor diastereomer), 34.2, 33.7, 31.7 (minor diastereomer), 31.6, 26.6, 26.2; MS (ESI) 
calculated for C29H39NO7 [M + H]+ m/z 514.28, found 514.18.   
 
Synthesis of (tert-butyl N-{3-[(4''-{4-[2-(morpholin-4-yl)ethoxy]phenyl} 
dispiro[adamantane-2,2'-[1,2,4]trioxolane-4',1''-cyclohexane]-7-
yl)formamido]propyl} carbamate (7). To a round bottom flask containing a Teflon-
coated magnetic stir bar under Ar(g) was added 4''-(4-(2-
morpholinoethoxy)phenyl)dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1''cyclohexane]-
5-carboxylic acid (6, 800 mg, 1.6 mmol, 1.0 equiv.), HATU (710 mg, 1.9 mmol, 1.2 
equiv.), N,N-diisopropylethylamine (0.678 ml, 3.9 mmol, 2.5 equiv.) and N,N-
dimethylformamide (15 mL). This dark orange solution stirred at room temperature 
under argon for 5 minutes before N-Boc-1,3-propanediamine (326 mg, 1.9 mmol, 1.2 
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equiv.) was added in one portion. The reaction was allowed to stir at room temperature 
for 16 hours at which point LCMS confirmed that the reaction had reached completion. 
The crude reaction was purified by preparatory HPLC (Waters XBridge C18 column, 25-
70% methanol/water with 0.05% formic acid) to afford (tert-butyl N-{3-[(4''-{4-[2-
(morpholin-4-yl)ethoxy]phenyl}dispiro[adamantane2,2'-[1,2,4]trioxolane-4',1''-
cyclohexane]-7-yl)formamido]propyl}carbamate (7, 365mg, 0.55mmol, 35%) as a white 
powder. This purification allowed separation of the roughly equal mixture of 
diastereomers, of which only the high Rf isomer was characterized and taken forward. 
1H NMR (400 MHz, CDCl3) δ 7.14-7.09 (m, 2H), 6.86-6.82 (m, 2H), 4.09 (t, 5.8 Hz, 2H), 
3.74 (t, 4.6 Hz, 4H), 3.30 (q, 6.3 Hz, 2H), 3.19-3.12 (m, 2H), 2.80 (t, 5.8 Hz, 2H), 2.61-
2.55 (m, 4H), 2.55-2.45 (m, 1H), 2.23-2.16 (m, 2H), 2.14–2.09 (m, 2H), 2.07-1.77 (m, 
15H), 1.77–1.56 (m, 6H), 1.46 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 177.3, 157.1, 
156.7, 138.5, 127.6, 114.5, 110.3, 108.9, 66.9, 65.7, 57.7, 54.0, 42.0, 39.8, 38.5, 38.0, 
36.9, 36.7, 36.2, 34.7, 33.7, 31.6, 28.4, 26.4; MS (ESI) calculated for C37H55N3O8 [M + 
H]+ m/z 670.41, found 670.35.  
 
Synthesis of N-(3-ammoniumpropyl)-4''-{4-[2-(morpholin-4-
yl)ethoxy]phenyl}dispiro[adamantane-2,2'-[1,2,4]trioxolane-4',1''-cyclohexane]-7-
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carboxamide formate (8, TRX-amine). To a round bottom flask containing a Teflon-
coated magnetic stir bar under Ar(g) was added (tert-butyl N-{3-[(4''-{4-[2-(morpholin-4-
yl)ethoxy]phenyl}dispiro[adamantane-2,2'[1,2,4]trioxolane-4',1''-cyclohexane]-7-
yl)formamido]propyl}carbamate (7, 225 mg, 0.3 mmol, 1.0 equiv.) and methanol (7.5 
mL). To this stirring solution was added acetyl chloride (0.72 ml, 10.1 mmol, 30.0 equiv.) 
dropwise over 5 minutes. The reaction was allowed to stir at room temperature for 140 
minutes at which point the reaction was determined to be complete by LCMS. To 
quench the reaction, the pH was adjusted to pH 7 through addition of saturated 
NaHCO3 (10 mL). The mixture was concentrated under reduced pressure to give a 
white slurry. To this slurry was added 1M Na2CO3 (20 mL) and CH2Cl2 (40 mL). The 
organic layer was collected and the aqueous layer was extracted with CH2Cl2 (2 x 25 
mL). The combined organic layers were transferred to an Erlenmeyer flask equipped 
with a stir bar to which was added water (75 mL). This stirring mixture was cooled to 
0˚C and the pH was adjusted to 1 through addition of formic acid. The aqueous layer 
was collected and washed with CH2Cl2 (2 x 40mL). N-(3ammoniumpropyl)-4''-{4-[2-
(morpholin-4-yl)ethoxy]phenyl}dispiro[adamantane-2,2'-[1,2,4]trioxolane-4',1''-
cyclohexane]-7-carboxamide formate (8, 218 mg, 100%) was obtained as a white fluffy 
solid following lyophilization of the aqueous layer. Characterization was of a mixture of 
isomers. 1H NMR (400 MHz, CDCl3) δ 7.13-7.04 (m, 2H), 6.86-6.77 (m, 2H), 4.07-4.02 
(m, 2H), 3.71-3.66 (m, 4H), 3.37-3.28 (m, 2H), 2.77-2.72 (m, 2H), 2.56-2.51 (m, 4H), 
2.502.40 (m, 1H), 2.16-2.09 (m, 2H), 2.07-1.74 (m, 19H), 1.72–1.55 (m, 4H); 13C NMR 
(100 MHz, CDCl3) δ 177.2, 157.0, 138.3, 127.5, 114.3, 110.2, 108.6, 66.8, 65.7, 57.6, 
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54.0, 41.8, 39.6, 39.2, 38.4, 37.8, 36.6, 36.1, 36.0, 34.5, 33.6, 31.5, 26.3; MS (ESI) 
calculated for C32H47N3O8 [M + H]+ m/z 570.35, found 570.21.   
 
Synthesis of N-(3-(4-fluorobenzamido)propyl)-4''-(4-(2-morpholinoethoxy)phenyl) 
dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1''-cyclohexane]-5-carboxamide (9, 
19F-TRX analytical standard). To a round bottom flask containing a Teflon-coated 
magnetic stir bar under Ar(g) was added N-(3-ammoniumpropyl)-4''-{4-[2-(morpholin-
4yl)ethoxy]phenyl} dispiro[adamantane-2,2'-[1,2,4]trioxolane-4',1''-cyclohexane]-7-
carboxamide formate (8, 10 mg, 0.018 mmol, 1.0 equiv.), N,N-diisopropylethylamine 
(0.006 ml, 0.033 mmol, 1.9 equiv.) and N,N-dimethylformamide (0.2 mL). To this stirring 
solution was added SFB (4 mg, 0.018 mmol, 1.0 equiv.) in one portion. The reaction 
was lowered into an oil bath that had been preheated to 50˚C and was allowed to stir 
under argon for 30 minutes. At this point, the reaction was determined to be complete 
by LCMS. The crude reaction was purified by preparatory HPLC (Waters XBridge C18 
column, 40-70% methanol/water with 0.05% formic acid) to afford N-(3-(4-
fluorobenzamido)propyl)-4''-(4-(2morpholinoethoxy)phenyl)dispiro[adamantane-2,3'-
[1,2,4]trioxolane-5',1''-cyclohexane]-5carboxamide (9, 19F-TRX) as a white powder (7 
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mg, 58%). 1H NMR (400 MHz, CDCl3) δ 7.957.88 (m, 2H), 7.17-7.09 (m, 4H), 6.87-6.82 
(m, 2H), 4.14-4.07 (m, 2H), 3.78-3.71 (m, 4H), 3.48-3.34 (m, 4H), 3.19-3.12 (m, 2H), 
2.84-2.77 (m, 2H), 2.63-2.56 (m, 2H), 2.56-2.46 (m, 1H), 2.24-1.65 (m, 23H); MS (ESI) 
calculated for C39H50FN3O7 [M + H]+ m/z 692.37, found 692.34.  
  
 
Scheme S2-3.  Synthesis of HC2-TRX  
Synthesis of N-(3-(4-ethynlbenzamido)propyl)-4''-(4-(2-morpholinoethoxy)phenyl) 
dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1''-cyclohexane]-5-carboxamide (HC2-
TRX). To a round bottom flask containing a Teflon-coated magnetic stir bar under Ar(g) 
was added 4''(4-(2-morpholinoethoxy)phenyl)dispiro[adamantane-2,3'-[1,2,4]trioxolane-
5',1''-cyclohexane]-5carboxylic acid (6, 50 mg, 0.1 mmol, 1.0 equiv.), HATU (56 mg, 0.1 
mmol, 1.5 equiv.), N,N-diisopropylethylamine (0.068 ml, 0.4 mmol, 4 equiv.) and N,N-
dimethylformamide (3 mL). To this stirring solution was added N-(3-aminopropyl)-4-
ethynylbenzamide4 (28 mg, 0.1 mmol, 1.2 equiv.) in one portion. The reaction was 
allowed to stir under argon for 30 minutes. At this point, the reaction was determined to 
be complete by LCMS. The crude reaction was purified by preparatory HPLC (Waters 
XBridge C18 column, 40-70% methanol/water with 0.05% formic acid) to afford N-(3-(4-
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ethynlbenzamido)propyl)-4''-(4-(2-morpholinoethoxy)phenyl)dispiro[adamantane-2,3'-
[1,2,4]trioxolane-5',1''-cyclohexane]-5-carboxamide (HC2-TRX) as a white foam (56 mg, 
82%). 1H NMR (400 MHz, CDCl3) δ (ppm) = 7.89 - 7.79 (m, 2H), 7.62 - 7.49 (m, 3H), 
7.11 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 6.40 - 6.31 (m, 1H), 4.13 (t, J = 5.5 Hz, 
2H), 3.83-3.69 (m, 4H), 3.48-3.30 (m, 4H), 3.24-3.16 (m, 1H), 2.87 (t, J = 5.5 Hz, 2H), 
2.71-2.63 (m, 4H), 2.61 (s, 1H), 2.60-2.41 (m, 1H), 2.25-1.59 (m, 1H), 13C NMR (100 
MHz, CDCl3) δ (ppm) = 178.1, 166.8, 156.8, 138.5, 134.3, 132.2, 127.6, 127.0, 125.1, 
114.4, 110.1, 108.8, 82.8, 79.3, 66.4, 65.2, 57.4, 41.9, 40.9, 39.9, 39.5, 38.5, 36.7, 36.1, 
36.0, 35.9, 35.6, 34.6, 33.6, 31.5, 29.8, 26.3; MS (ESI) calculated for C41H51N3O7 [M + 
H]+ m/z 698.37, found 698.24.  
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Chapter 3: An Fe(II)-reactive prodrug strategy selectively delivers 
MEK inhibitors to KRAS-driven cancers while mitigating known 
clinical toxicities. 
Muir, R.K., Jiang, H., Gonciarz, R.L., Renslo, A.R., Collisson, E. A. 
INTRODUCTION 
The field of oncology is progressively moving closer to the ideal of “personalized 
medicine,” in which weaknesses in a patient’s cancer are identified and exploited with a 
matching chemotherapy.1,2 For example, patients identified as having mutations in the 
MAP kinase pathway will be administered MEK inhibitors to stop the aberrant signaling 
pathway. While these targeted therapeutics can show remarkable antitumor activity, 
many times they carry significant side-effects in the clinic due to on-target, off-tissue 
activity. In the case of patients administered MEK inhibitors, these drugs are known to 
cause serious skin rashes and ocular toxicities in 10-20% of patients, often limiting the 
dosing regimen.3 This suggests MEK inhibitors as a candidate for a prodrug strategy as 
a method to mitigate on-target, off-tissue activity in vivo. 
The Renslo lab has recently reported an Fe(II)-activated prodrug platform that can 
selectively deliver amine-bearing payloads to cancer cells with an elevated labile iron 
pool (LIP).4 However, little information is known clinically about what oncogenic drivers 
or cancer subtypes are associated with an elevated LIP. While nodes of iron 
metabolism regulation are generally highly regulated in healthy tissues, various cancers 
have been noted to alter expression levels in this pathway indicating an increased 
avidity for iron.5,6 Many cancers have been observed to upregulate transferrin receptor 
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levels, though no clear connection between this upregulation and oncogenic driver or 
cancer subtype has been clearly established. Here we hypothesize that oncogenic 
mutations of KRAS are connected to this elevated LIP, and that we can leverage this as 
a method to selectively deliver MEK inhibitors to KRAS-driven cancers while mitigating 
known on-target, off-tissue toxicities. 
RESULTS AND DISCUSSION 
PET/CT imaging of 68Ga accumulation in cancers bearing KRAS mutations 
As 97% of patients with pancreatic ductal adenocarcinoma (PDAC) harbor a KRAS 
mutation as their primary oncogenic driver,7,8 we hypothesized these tumors would have 
an upregulated transferrin receptor level. Through PET/CT imaging, a metastasis 
originating from PDAC can be seen to accumulate 68Ga and readily identified by 
PET/CT imaging (Fig 3-1A). To further investigate this link between KRAS-driven 
cancers and increased avidity for iron, we performed several preclinical PET/CT 
imaging studies. Mice bearing xenografts with wild type KRAS expression or with 
oncogenic KRAS mutations were injected with 68Ga-loaded transferrin. Those bearing a 
KRAS mutation accumulate significantly more of this Fe(III) mimetic than other 
xenografts (Fig 3-1B), suggesting KRAS mutations play a role in altering iron 
metabolism. 
KRAS mutation increases the reactive Fe(II) pool in cells 
While the PET/CT imaging studies suggest an increased avidity for Fe(III) in KRAS-
driven cancers, it does not inform on aberrant levels of reactive Fe(II) found in the labile 
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Figure 3-1: a) PET imaging with 68Ga (an Fe3+ mimetic) detects a bone metastasis from a patient with 
pancreatic ductal adenocarcenoma. b) 68Ga PET  imaging of mice bearing xenografts with wild type or 
mutant KRAS. Tumors bearing an oncogenic KRAS mutation have an increased avidity for 68Ga, 
indicating an elevated level of transferrin receptor. 
 
iron pool (LIP). To assess the effect of KRAS mutations on the LIP, mouse fibroblasts 
were transfected with TGT-hKRAS-G12D and treated with FerroFar Red, a probe for 
labile Fe(II).9 A significantly elevated Fe(II) pool can be detected 72 hour post-
transfection (Fig 3-2A), around the same time these cells reached maximum expression 
of mutant KRAS (Fig 3-2B). This finding was confirmed with an orthogonal Fe(II) probe, 
TRX-PURO (Fig 3-2D),10 suggesting a single mutation to KRAS can significantly alter 
the cellular labile iron pool. 
The concentration of the labile iron pool was then determined in a panel of cancer cell 
lines with FerroFar Red. Notably, the pancreatic cancer cell lines bearing KRAS 
mutations had approximately 10X more reactivity with the probe than the breast cancer 
cell lines with wild type KRAS expression (Fig 3-2E). This data in combination with the 
PET/CT imaging experiment suggest that KRAS is altering the cellular iron metabolism 
to increase both the cells avidity for Fe(III) and an elevated intracellular labile iron pool. 
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Figure 3-2 a) Mouse fibroblasts were transfected with TGT-hKRAS-G12D. Fe(II) concentration was 
monitored through SiRhoNox b) Transfection was confirmed via Western Blot. Both an increase in KRAS 
G12D as well as pERK can be observed over 72 hours. c) Quantification of transfected fibroblasts treated 
with SiRhoNox. An increase in Fe(II) can be observed by 72 hours post-transfection. d) An elevated Fe(II) 
pool in KRAS-transfected cells was confirmed with TRX-PURO, an alternative Fe(II)-specific probe. e) 
The Fe(II) levels were determined in various breast and pancreatic cancer cell lines via flow cytometry 
after treatment with SiRhoNox. All pancreatic cancer cell lines appear to have more Fe(II) than breast. 
 
The elevated labile pool in KRAS-driven pancreatic cancers can be exploited by 
an Fe(II)-activated prodrug strategy 
There are several pharmacological examples of leveraging an elevated labile iron pool.5 
The Renslo lab has historically leveraged the Fe(II) reactivity of 1,2,4-trioxolanes (TRX) 
as a method to selectively deliver amine-containing payloads to areas of elevated 
ferrous iron.11,12 Previous work has focused on delivering bulk cytotoxins in these 
cancer cells. In this work, we explore the idea of coupling a targeted therapeutic in 
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Cobimetinib, a clinically approved MEK inhibitor with serious clinical toxicities. 
Cobimetinib readily reacts with our previously described coupling conditions to generate 
a trioxolane-caged Cobimetinib (TRX-COBI, Fig 3-3B).  
When introduced to several pancreatic cancer cell lines, TRX-COBI demonstrates 
sufficient uncaging and subsequent MEK inhibition by Western blot (Fig 3-3C). The 
antitumor activity of TRX-COBI was then tested across a panel of breast and pancreatic 
cancer cell lines. A TRX-COBI susceptibility ratio was obtained by normalizing the GI50 
of TRX-COBI to that of parent Cobimetinib. Interestingly, each pancreatic cancer cell 
line was more susceptible to TRX-COBI than any of the breast cancer lines, consistent 
with the elevated reactive Fe(II) pool observed with FerroFar Red. 
TRX-COBI shows equivalent MEK inhibition and antitumor activity as parent 
Cobimetinib across several preclinical models 
The MEK inhibition and antitumor activity of TRX-COBI was then assessed in vivo. Mice 
bearing KRAS-driven xenografts or PDX models were treated with equimolar doses of 
Cobimetinib or TRX-COBI for 20 days. TRX-COBI shows similar MEK inhibition (Fig 3-
4A) and growth inhibition (Fig 3-4B) as parent Cobimetinib. This trend holds true in 
more clinically-relevant models as well. First the efficacy of TRX-COBI was examined in 
PDAC.fLuc (KrasG12D) mice. These mice bear KRAS-driven xenografts implanted in the 
pancreas which more accurately represents the pancreatic cancer tumor environment. 
While tumor volume cannot be monitored with calipers due to the xenograft location, it 
can be estimated by monitoring luciferase activity. Significant tumor growth inhibition is 
be observed after 20 days of dosing with equimolar COBI or TRX-COBI (Fig 3-4C). This 
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Figure 3-3: a) A general reaction mechanism of TRX-based prodrugs to afford traceless release of amine-
containing payloads upon reaction with Fe(II). b) TRX-COBI can be readily synthesized by reacting 
parent Cobimetinib with previously reported TRX-PNP. c) Three pancreatic cancer cell lines were dosed 
with either Cobimetinib (COBI) or TRX-COBI for 6 hours. On-target inhibition of MEK can be observed by 
Western blot. d) A panel or breast and pancreatic cancer cells were dosed with COBI and TRX-COBI for 
72 hours. The GI50 of TRX-COBI for each cell was normalized to that of parent COBI to generate a TRX 
susceptibility ratio. 
 
is further confirmed by reduced tumor weight determined after death (Fig 3-4D).   
This experiment was then repeated in KPT mice (KrasLSLG12D/+; p53flox/flox; R26tdTomato/+), 
often considered the “gold standard” preclinical model in the field of KRAS-driven 
cancer.13 Dosing began 20 days after intratracheal administration of Ad-CRE and 
continued daily for 60 days. Mice treated with equimolar doses of Cobimetinib and TRX-
COBI showed considerable growth inhibition of the tumor compared to vehicle treated  
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Figure 3-4: a) Tissue slices of tumors taken from mice treated with either Cobimetinib (COBI, 7.5 mg/kg), TRX-COBI 
(12.5 mg/kg) or vehicle. On-target inhibition of MEK is visualized by staining for pERK via immunohistochemistry. b) 
TRX-COBI has similar antitumor activity of an equimolar dose of COBI in a KRAS-driven PDX model. c) Mice bearing 
p53.luc tumors after 15 days of dosing with COBI (7.5 mg/kg), TRX-COBI (12.5 mg/kg) or vehicle. Tumor volume can 
be measured by luminescence. d) Tumors of the mice from c were excised and weighed. TRX-COBI again maintains 
similar antitumor activity to parent Cobimetinib. e) Excised lungs from KPT mice after 60 days of dosing. TRX-COBI 
and COBI greatly reduce tumor growth. f) Kaplan-Meier survival curve of mice from e (n=10 per arm). 
 
mice (Fig 3-4E). Interestingly, all mice dosed with TRX-COBI survived the duration of 
the study (Fig 3-4F) while showing negligible adverse reactions to the treatment. 
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Known on-target off-tissue toxicities of MEK inhibitors are mitigated by TRX-COBI 
As mentioned previously, MEK inhibitors used in the clinic carry severe side-effects, 
most significantly in the skin (rash) and eyes (chorioretinopathy). These are now known 
to be the result of on-target yet off-tissue activity, meaning Cobimetinib is inhibiting 
normal MAPK signaling in these tissues. These tissues are not known to have an 
aberrant iron metabolism, so it would be expected that TRX-COBI would remain fully 
caged and inactive in these areas of known clinical toxicity. 
The MEK inhibition of TRX-COBI was assessed in retinal pigment epithelia cells (RPE-
1) and keratinocytes (HaCaT). Strikingly, TRX-COBI shows highly reduced MEK 
inhibition in these cells when compared to Cobimetinib (Fig 3-5a), indicating a lack of 
TRX-fragmentation and uncaging. In preclinical models, MEK inhibitors are known to 
cause a reduction in the epidermal layer.14 Tail samples were collected from mice dosed 
with TRX-COBI (12.5 mg/kg), Cobimetinib (7.5 mg/kg) or vehicle for 20 days and the 
epidermal thickness was determined. While mice dosed with Cobimetinib showed 
significant reduction in epidermal layer, remarkably those mice dosed with TRX-COBI 
showed no statistical difference compared to those dosed with vehicle. This data 
combined with the mitigated in vitro activity suggests the clinical on-target off-tissue 
toxicities of Cobimetinib are sufficiently caged by dosing with TRX-COBI.  
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Figure 3-5: Caged on-target off-tissue activity of TRX-COBI. a) Western blot showing caged MEK-inhibition of TRX-
COBI in retinal pigment epithelial (RPE-1) and keratinocyte (HaCaT) cell lines while maintaining on-target inhibition in 
a pancreatic cancer cell line (Mia-Paca-2). b) Representative tissue slices of mouse tails dosed with COBI (7.5 
mg/kg), TRX-COBI (12.5 mg/kg), or vehicle. Prolonged MEK inhibition causes a reduction of epidermal thickness as 
observed in mice treated by COBI. Quantification shows no statistical difference between mice treated with TRX-
COBI and vehicle (n=5 per arm).  
 
CONCLUSIONS AND FUTURE DIRECTIONS 
Here we report utilizing the TRX-prodrug platform to selectively deliver Cobimetinib, a 
clinically approved MEK inhibitor, to KRAS-driven cancers. TRX-COBI shows similar on-
target activity and growth inhibition to parent Cobimetinib across several pancreatic 
cancer cell lines. This trend holds true across several preclinical models, including the 
“gold standard” KPT model. Pleasingly, TRX-COBI shows masked activity in areas of 
known clinical toxicities caused by on-target, off-tissue activity both in vitro and in vivo.  
The major future direction of this project is to use TRX-COBI in combination with other 
chemotherapies for which Cobimetinib could not be used. For example, PI3K inhibitors 
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have long been desired to be used in combination with MEK inhibitors as tumors 
primarily driven by one of these pathways will often “escape” targeted therapeutics 
through the other pathway. However, combining PI3K and MEK inhibitors have proven 
to carry too severe side-effects to be used effectively in the clinic. By caging the off-
tissue toxicities of a MEK inhibitor, we hypothesize TRX-COBI could be used safely in 
combination with PI3K inhibitors. Preclinical studies are currently being performed to 
test this hypothesis. 
 
MATERIALS AND METHODS 
Cell Line and Cell Culture 
Cells were maintained in an atmosphere of 5% CO2 in RPMI 1640 or DMEM media 
purchased from HyClone supplemented with 10% FBS (Gibco) and Pen/Strep (1× final 
concentration, Gemini BioProducts).  
 
In vitro inhibition 
In vitro inhibition was determined using the HDAC-Glo I/II screening system (Promega). 
Compounds were dissolved in DMSO then diluted in buffer to give a final concentration 
of 0.1% DMSO. Signal was read using the Flexstation 3 (Molecular Devices) 
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Western Blots 
Cells were plated in 6-well plate at 106 cells per well and incubated for at least 24 h prior 
to exposure to compounds. Cells were then treated with specified concentrations of 
compound that resulted in a final concentration of 0.1% DMSO. After the specified 
amount of time, cells were pelleted by centrifuging at 200 x g for 5 minutes. Cell pellets 
were washed with PBS and then lysed with mPER lysis buffer (Thermo Fisher) 
containing protease inhibitor cocktail (1x concentration, Sigma). Protein concentration 
was determined using Pierce BCA assay (Thermo Fisher). Samples were normalized to 
20 µg per well and run on a 4-12% Bis-Tris Protein Gel (Thermo Fisher). Transfer and 
blotting was performed using the iBlot 2 and iBind system (Thermo Fisher). 
Cell toxicity assay 
Cells were plated in 96-well Greiner black µClear tissue culture plates at 104 cells per 
well for at least 24 h prior to exposure to compounds. Cells were then treated in 
triplicate with escalating concentrations of compound performed in media containing a 
final concentration of 0.1% DMSO and 200 µL of media per well. Cell viabilities were 
determined 72 h after treatment by Cell-Titer Glo assay (Promega) on the Flexstation 3 
reader (Molecular Devices). Relative luminescent units (RLU) were plotted against 
corresponding drug concentrations and fitted with a standard four-parameter sigmoidal 
curve with GraphPad Prism 6. Data reported at the IC50, and error bars represent SEM 
(n = 3).  
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Pharmacokinetic Assays 
NSG mice were administered a single IP dose of TRX-COBI (12.5 mpk, n=3). Blood 
was collected at indicated timepoints and from which drug concentrations were 
determined by Integrated Analytical Solutions, Inc (Berkeley, CA). 
 
Other 
Graphing and analysis of data were done using GraphPad Prism 6 software and 
Microsoft Excel 2010. Figures were prepared with Microsoft Powerpoint and Adobe 
Design Standard CS6 software. 
 
SUPPLEMENTAL INFORMATION 
General Information  
All reactions were performed under an Argon atmosphere using anhydrous solvents 
obtained from commercial suppliers in oven-dried round-bottom flasks containing Teflon 
coated stirrer bars, unless otherwise noted. All anhydrous solvents used were 
purchased from Sigma-Aldrich and used without further purification. Solvents to be 
employed in flash column chromatography and reaction work-up procedures were 
purchased from either Sigma-Aldrich or Fisher Scientific. All other reagents were 
obtained commercially and used without further purification, unless otherwise stated. Air 
and/or moisture sensitive reagents were transferred via syringe and were introduced 
into reaction vessels through rubber septa. Reactions were monitored using thin layer 
		 56	
chromatography (TLC), performed on 0.25-mm EMD pre-coated glass-backed silica gel 
60 F-254 plates. Column chromatography was performed on Silicycle Sili-prep 
cartridges using a Biotage Isolera Four automated flash chromatography system.  
Compounds were visualized under UV light or through staining with permanganate, 
iodine, or most preferably for trioxolane analogs, Seebach’s “Magic” stain (composed of 
the following: 2.5 g phosphomolybdic acid, 1.0 g cerium sulfate, 6 mL concentrated 
sulfuric acid, and 94 mL water). Solutions containing crude reaction mixtures, as well as 
those obtained upon reaction work-up, and chromatography fractions were first 
concentrated by rotary evaporation at temperatures under 40 ˚C, at 20 Torr then 
subsequently placed under Hi-Vac at 0.5 Torr unless otherwise indicated.  
 
Instrumentation 
NMR spectra were recorded on either a Varian INOVA 400 MHz spectrometer (with 5 
mm Quad-Nuclear Z-Grad Probe), or a Bruker AvanceIII HD 400 MHz (with 5mm BBFO 
Z-gradient Smart Probe), calibrated to CH(D)Cl3 as an internal reference (7.26 and 
77.00 ppm for 1H and 13C NMR spectra, respectively). Data for 1H NMR spectra are 
reported in terms of chemical shift (δ, ppm), multiplicity, coupling constant (Hz), and 
integration. Data for 13C NMR spectra are reported in terms of chemical shift (δ, ppm), 
with multiplicity and coupling constants in the case of C–F coupling. The following 
abbreviations are used to denote the multiplicities: s = singlet; d = doublet; dd = doublet 
of doublets; dt = doublet of triplets; dq = doublet of quartets; ddd = doublet of doublet of 
doublets; t = triplet; td = triplet of doublets; tt = triplet of triplets; q = quartet; qd = quartet 
of doublets; quin = quintet; sex = sextet; m = multiplet. LC-MS and compound purity 
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were determined using Waters Micromass ZQ 4000, equipped with a Waters 2795 
Separation Module, Waters 2996 Photodiode Array Detector, and a Waters 2424 ELSD. 
Separations were carried out with an XBridge BEH C18, 3.5µm, 4.6 x 20 mm column, at 
ambient temperature (unregulated) using a mobile phase of water-methanol containing 
a constant 0.1 % formic acid.  
	
Scheme S3-1: Synthesis of TRX-PNP 
 
(R)-3-((tert-butyldiphenylsilyl)oxy)cyclohexan-1-one (1). A 200-mL RBF equipped 
with a stirbar, rubber septum, and argon inlet was charged with (R)-3-
hydroxycyclohexan-1-one15 (2.1 g, 18.4 mmol, 1.0 equiv), N,N-dimethylformamide (40 
mL), and imidazole (2.51 g, 36.8 mmol, 2.0 equiv). The mixture was cooled at 0 °C 
while tert-butyl(chloro)diphenyl silane (5.3 mL, 20.2 mmol, 1.1 equiv) was added 
dropwise via syringe. The reaction mixture was allowed to slowly warm to room 
temperature. After stirring for 16 h, the reaction was deemed to be incomplete based on 
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TLC and LCMS analysis. The reaction mixture was then diluted with 100 mL of EtOAc 
and 100 mL H2O. The organic phase was separated and washed with two 50 mL 
portions of brine, dried over MgSO4, filtered, and concentrated to afford a colorless oil. 
The residue was purified through flash column chromatography (330 g silica gel 
cartridge, 0–20% EtOAc/Hexanes, product eluted during 8% EtOAc/Hex) to yield the 
product (6.01 g, 93%) as a colorless oil. 1H NMR (400 MHz, CHLOROFORM-d) δ 1.08 - 
1.12 (s, 9 H), 1.64 - 1.71 (m, 1 H), 1.78 - 1.83 (m, 2 H), 2.17 (br dd, J=8.46, 5.78 Hz, 1 
H), 2.25 - 2.32 (m, 1 H), 2.35 - 2.42 (m, 1 H), 2.47 (d, J=4.99 Hz, 2 H), 4.23 (t, J=4.93 
Hz, 1 H), 7.39 - 7.49 (m, 6 H), 7.68 - 7.72 (m, 4 H); 13C NMR (100 MHz, 
CHLOROFORM-d) δ 19.2, 20.6, 26.6, 26.9, 32.9, 41.2, 50.4, 71.1, 127.69, 127.72, 
129.8, 129.9, 133.6, 133.9, 134.9, 135.7, 135.8, 210.0; MS (ESI) calculated for 
C22H29O2Si [M + H]+ m/z 353.19, found 353.46. 
 
(1R,3R)-tert-butyl((dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1''-cyclohexan]-3''-
yl)oxy)diphenylsilane (2). A 200-mL recovery flask was charged with silyl ketone, 1 
(1.51 g, 4.28 mmol, ca. 1 equiv), carbon tetrachloride (100 mL), and O-methyl 2-
adamantanone oxime2 (768 mg, 4.28 mmol, 1 equiv). This solution was then cooled to 0 
˚C and subsequently sparged with O2 for 10 minutes. The reaction was kept at 0 ˚C 
while ozone was bubbled (2 L/min, 40% power) through the solution. After stirring for 90 
mins, the reaction was deemed to be incomplete based on TLC and LCMS analysis and 
additional oxime (0.386 g, 2.14 mmol, 0.5 equiv) was added in a single portion to the 
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reaction. Additionally, carbon tetrachloride (50 mL) was added to the solution. Ozone 
was bubbled through the reaction for another 45 mins, the LCMS indicated the ratio of 
pruduct formation: silyl ketone was 2:1. Another 0.5 eq of oxime (0.386 g, 2.14 mmol, 
0.5 equiv) was added in a single portion to the reaction, and ozone was bubbled 
through the reaction for another 45 mins, at which point the reaction was determined to 
be complete based on LCMS and TLC analysis. The solution was then purged with O2 
for 10 minutes in an effort to remove any dissolved ozone, followed by sparging with 
argon gas for 10 minutes to remove any dissolved oxygen. The solution was then 
concentrated under reduced pressure to provide an extremely viscous oil. The residue 
was purified through flash column chromatography (120 g silica gel cartridge, 0–20% 
EtOAc/Hexanes, product eluted during 5% EtOAc/Hex) to yield product (2.01 g, 91%) 
as a white foamy solid. The diastereoselectivity of the Griesbaum coozonolysis was 
determined to be 12:1 in favor of the trans diastereomer. 1H NMR (400 MHz, 
CHLOROFORM-d) δ 1.08 (s, 9 H), 1.19 - 1.36 (m, 3 H), 1.46 - 1.65 (m, 3 H), 1.65 - 1.84 
(m, 12 H), 1.95 - 2.05 (m, 3 H), 3.78 - 3.85 (m, 1 H), 3.89 - 3.96 (m, 1 H), 7.36 - 7.46 (m, 
6 H), 7.69 (td, J=7.67, 1.46 Hz, 4 H); 13C NMR (100 MHz, CHLOROFORM-d) δ 19.2, 
19.9, 26.5, 26.9, 27.0, 33.2, 33.8, 34.4, 34.8 ,36.2, 36.3, 36.8, 43.8, 69.8, 109.2, 111.2, 
127.5, 127.6, 129.5, 129.6, 134.4, 134.5, 135.75, 135.78;  MS (ESI) calculated for 
C32H42NaO4Si [M + Na]+ m/z 541.28, found 541.56. 
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(1R,3R)-Dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.13,7]decan]-
3-ol (3). 
To a stirred solution of 2 (2.0 g, 3.86 mmol, 1 equiv) in THF (20 mL) was added a 
solution of tetrabutylammonium fluoride (1.0 M in THF, 19.2 ml, 19.3 mmol, 5 equiv) 
dropwise to this solution while stirring at 0 °C. The reaction mixture was left to warm 
slowly to room temperature and stirred for 12 h, at which point it was determined to be 
complete based on TLC and LCMS analysis. The reaction was then diluted with brine 
(100 mL) and extracted with EtOAc (100 mL x 2). The organic layer was then dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford a yellow 
oil. The residue was then purified through flash column chromatography (80 g silica gel 
cartridge, 0–50% EtOAc/Hexanes, product eluted during 20% EtOAc/Hexanes) to yield 
the product (1.01 g, 93%) as a white powder: 1H NMR (400 MHz, CHLOROFORM-d) δ 
1.47 - 1.63 (m, 2 H), 1.69 - 1.88 (m, 12 H), 1.90 - 2.05 (m, 7 H), 2.07 (d, J=4.02 Hz, 1 
H), 2.47 (br s, 1 H), 3.94 - 4.14 (m, 1 H); 13C NMR (100 MHz, CHLOROFORM-d) δ 
19.1, 26.4, 26.8, 33.1, 33.8, 34.7, 34.8, 34.9, 34.9 , 36.2, 36.2, 36.7, 41.7, 67.9, 109.1, 
111.9; MS (ESI) calculated for C16H24O4 [M + H]+ m/z 281.17, found 281.51. 
 
 
(1R,3R)-3-(p-Nitrophenoxycarbonyloxy)dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-
5',2''-tricyclo[3.3.1.13,7]decane] (4). To an oven-dried round bottom flask containing a 
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magnetic stir bar under an Ar(g) atmosphere was added alcohol 3 (0.150 mg, 0.54 
mmol, 1.0 equiv) dissolved in dichloromethane (10 mL), N,N-diisopropylethylamine 
(0.30 mL, 1.74 mmol, 3.25 equiv), and 4-dimethylaminopyridine (0.078 g, 0.64 mmol, 
1.2 equiv). The mixture was cooled to 0 °C while 4-nitrophenyl chloroformate (0.350 g, 
1.74 mmol, 3.25 equiv) was added as a solid in two portions. The solution was allowed 
to stir at room temperature for 3 hours. The reaction was then diluted with DI H2O (100 
mL) and subsequently extracted with EtOAc (100 mL). The organic layer was washed 
repeatedly by potassium carbonate solution until the aqueous layer was colorless and 
no longer yellow (meaning that all of the p-nitrophenol had been successfully removed 
from the organic layer). The organic layer was dried over anhydrous Na2SO4, filtered, 
and concentrated under reduced pressure to yield thick yellow oil. The residue was then 
purified through flash column chromatography (80 g silica gel cartridge, 0–25% 
EtOAc/Hexanes, product eluted during 10% EtOAc/Hex) to yield the desired product 
(208 mg, 87%) as a pale yellow oil (93:7 dr). 1H NMR (400 MHz, CHLOROFORM-d) δ 
8.26 (d, J=9.13 Hz, 2 H), 7.38 (br d, J=9.13 Hz, 2 H), 4.94 (td, J=9.19, 4.50 Hz, 1 H, 
minor diastereomer), 4.79 - 4.88 (m, 1 H), 2.32 - 2.42 (m, 1 H), 2.10 (br d, J=8.77 Hz, 1 
H), 1.69 - 2.00 (m, 1 H), 1.64 - 2.01 (m, 17 H), 1.40 - 1.64 (m, 3 H), 1.20 - 1.28 (m, 1 H), 
0.83 - 0.96 (m, 1 H); 13C NMR (100 MHz, CHLOROFORM-d) δ 19.5, 26.4, 26.8, 30.0, 
33.5, 34.7, 34.7, 34.7, 34.8, 36.3, 36.3, 36.7, 39.5, 76.2, 108.3, 111.9, 
121.7,121.9,125.3,145.3,151.6, 155.5; MS (ESI) m/z [M+H]+ calcd for C23H27NNaO8: 
468.16; found 467.99. 
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(3''R,4'R)‐dispiro[adamantane‐2,2'‐[1,2,4]trioxolane‐4',1''‐cyclohexan]‐3''‐yl (2R)‐
2‐(1‐{3,4‐difluoro‐2‐[(2‐fluoro‐4‐iodophenyl)amino]benzoyl}‐3‐hydroxyazetidin‐
3‐yl)piperidine‐1‐carboxylate (TRX-COBI). To an oven-dried round bottom flask 
containing a magnetic stir bar under an Ar(g) atmosphere was added Cobimetinib 
(0.150 mg, 0.28 mmol, 1 eq) and TRX-PNP 4 (0.150 mg, 0.34 mmol, 1.2 equiv) 
dissolved in dimethylformamide (10 mL), N,N-diisopropylethylamine (0.30 mL, 1.74 
mmol, 6 equiv), and 4-dimethylaminopyridine (0.038 g, 0.34 mmol, 1.2 equiv). The 
solution was allowed to stir at room temperature for 3 hours to 72 hours, monitoring 
reaction progress by LCMS. The reaction was then diluted with DI H2O (100 mL) and 
subsequently extracted with EtOAc (100 mL). The organic layer was washed repeatedly 
with a satd. sodium bicarbonate solution until the aqueous layer was colorless and no 
longer yellow. The organic layer was dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure to yield thick yellow oil. The residue was then 
purified through flash column chromatography (40 g silica gel cartridge, 0–50% 
EtOAc/Hexanes, 0-15% MeOH + 0.7N NH3/DCM, product eluted during 40% 
EtOAc/Hex, unreacted Cobimetinib eluted during 15% MeOH + 0.7N NH3) to yield the 
desired product (30-50%) as a white solid. 1H NMR (1H NMR (400 MHz, CDCl3) δ 8.60 
(br s, 1 H), 8.41 (br s, 1 H), 7.39 (dd, J = 10.4, 1.6 Hz, 1 H), 7.31 - 7.34 (m, 1 H), 7.32 
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(d, J = 8.5 Hz, 1 H), 7.15 (br s, 1 H), 6.82 (app q, J = 1.0 Hz, 1 H), 6.61 (app td, J = 8.5, 
5.6 Hz, 1 H), 5.45 (br s, 1 H), 4.88 (br s, 1 H, minor diastereomer), 4.76 (app spt, J = 1.0 
Hz, 1 H), 4.11 - 4.25 (m, 2 H), 3.93 - 4.11 (m, 3 H), 3.22 - 3.44 (m, 1 H), 2.87 (br s, 1 H), 
2.07 - 2.25 (m, 1 H), 1.86 - 2.02 (m, 8 H), 1.72 - 1.85 (m, 7 H), 1.46 - 1.65 (m, 6 H), 1.21 
- 1.46 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ 169.1, 155.4, 154.4 (d, J = 248.7), 153.0 
(d, J = 253.1), 152.6 (d, J = 252.4), 143.5 (d, J = 250.2), 143.4 (br d, J = 250.2), 142.2, 
132.9 (d, J = 3.7 Hz), 132.6 (br d, J = 3.7 Hz) 130.8 (br d, J = 10.3 Hz), 124.3 (d, J = 
21.3 Hz), 119.9, 119.6, 119.2, 111.8, 109.1 (br d, J = 17.6), 108.5, 108.3 (minor 
diastereomer), 81.6 (d, J = 7.3 Hz), 77.3, 72.0, 70.9 (br s), 65.7, 65.2, 64.9 (minor 
diastereomer), 60.3, 60.1 (minor diastereomer), 48.0 (br s), 39.6, 36.7, 36.3 (minor 
diastereomer), 36.1, 34.9 (minor diastereomer), 34.7, 34.0, 33.9 (minor diastereomer), 
30.5, 30.2 (minor diastereomer), 29.7 (minor diastereomer), 26.9, 26.4, 25.4, 25.0 (br s), 
24.1 (br s), 19.5, 19.4 (minor diastereomer), several minor diastereomer peaks 
overlapping or not observed; LRMS (ESI): RT = 13.1 mins (diode array), calcd for 
C38H43F3IN3O7Na [M + Na]+: 860.20, found: 860.15; HRMS (ESI) calcd for 
C38H43F3IN3O7Na [M + Na]+: 860.1995, found: 860.1975 
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Chapter 4: Towards the development of Fe(II)-activated prodrugs of 
histone deacetylase inhibitors as selective anti-myeloma agents 
Muir, R.K., Blank, B.R., Steri, V., Hann, B., Renslo, A.R. 
INTRODUCTION 
Histone deacetylase (HDAC) inhibitors are a class of chemotherapeutics that target the 
DNA regulation pathways in cancer. There are several classes of HDACi approved as 
either monotherapy or in combination therapies as anticancer agents.1 Despite 
structural differences, HDAC inhibitors share a wide array of toxicities in the clinic, 
namely thrombocytopenia, neutropenia, fatigue, nausea and cardia arrythmia2,3 
Subsequent work to reduce toxicity revolved primarily around developing isoform-
specific HDAC inhibitors, however these molecules shared the same toxicities seen by 
pan-HDAC inhibitors. This indicates that the toxicity seen is due to on-target, yet off-
tissue inhibition and may be mitigated by tissue-specific delivery of these agents. 
To address this problem, a few HDAC inhibitor prodrugs have reported, yet only one 
has reported any results from preclinical models.4,5 Slusher et al reported an ester-
based prodrug approach to improve oral absorption and observed complete conversion 
to the free hydroxamic acid in mouse plasma within an hour.6 Recently, the Renslo ab 
has described a method for Fe(II)-sensitive caging the hydroxamate-containing LpxC 
inhibitor that showed promising in vivo efficacy against an acute P. aeruginosa infection 
model.7 Here is described the progress towards utilizing the same caging method on 
Panobinostat as a method to cage known clinical toxicities while maintaining its 
antimyeloma activity in preclinical models. 
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RESULTS AND DISCUSSION 
Synthesis of TRX-PANO 
To access the TRX-PANO scaffold, we attempted to utilize the same coupling scheme 
that was used to make another trioxolane-caged hydroxamate TRX-LpxC. Panobinostat 
acid 7 was synthesized as previously described,7 however the primary products 
observed were the result of polymerization reactions. A variety of protecting group 
strategies were attempted, with nosyl selected due to it providing the most efficient 
deprotection after the coupling reaction. 
 
 
Scheme 4-1: Panobinostat methyl ester 1 was protected with nosyl chloride to give ester 2. Following 
saponification, nosyl-protected panobinostat acid 3 was coupled with TRX-Hydroxylamine 6 via 
EDC/HOBT to give nosyl-TRX-PANO 4. Deprotection via thiophenol under basic conditions yielded TRX-
PANO 5. 
 
Cellular activity of TRX-PANO in Multiple Myeloma lines 
TRX-PANO was then tested for antimyeloma activity in relation to parent Panobinostat 
in three multiple myeloma lines. TRX-PANO shows dose-dependent cytotoxicity similar 
to Panobinostat, yet in all three cells the EC50 is shifted 5-8 fold less potent (Fig 4-1A). 
This is consistent with previously reported TRX-based prodrugs and is assumed to be 
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due to the variation in the concentration of the LIP in these cells.8,9 To confirm this 
activity was due to uncaging and subsequent on-target inhibition of HDACs, cells were 
exposed to either 100 nM of TRX-PANO or PANO and an accumulation of acetylated-
H4 was observed after 24 h (Fig 4-1B). This accumulation of acetylated-H4 occurs in a 
dose-dependent fashion in MM.1S cells after 24 h of dosing indicating sufficient 
uncaging and subsequent on-target activity. 
 
 
Figure 4-1 a) Multiple myeloma cell lines were treated with TRX-Pano or Panobinostat for 72 hours. 
Cytotoxicity was measured via CellTiter Glo. While TRX-Pano does show a shift in potency, it is still a 
highly cytotoxic compound to these cells. B) To ensure for on-target inhibition, cells were treated with 
either 100 nM PANO, TRX-PANO or DMSO for 24 hours. At this point, HDAC inhibition was measured by 
Western blot for acetylated H4. C) MM.1S cells were treated with TRX-PANO or PANO for 24 hours. A 
dose-dependent inhibition of HDACs is observed though potency appears to be less as seen in the 
cytotoxicity assay 
 
TRX-PANO faces issues in vivo due to metabolic instability in mice 
With promising cellular data, pharmacokinetic properties of TRX-PANO in NSG mice 
were determined (Figure 4-3C). However over 24 hours, no TRX-PANO was observed 
in the plasma of these mice. Instead a typical plasma concentration curve was observed  
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Figure 4-2: TRX-PANO is readily hydrolyzed by CES1 found in abundance in mouse plasma. This is in 
stark contrast to TRX-LpxC stability 
 
of a hydrolyzed product, PANO-Acid 7, indicating the parent TRX-PANO to be a 
substrate for a hydrolase. This data is in direct opposition to the stability of previously 
reported TRX-caged hydroxamate, TRX-LpxC (Figure 4-2). The instability of TRX-
PANO combined with the lack of preclinical data of other non-branching hydroxamate-
based prodrugs suggests that hydroxamate esters lacking a quaternary center at the 
alpha-position are intrinsically unstable due to one or more hydrolases found in vivo. 
Fortunately at the same time as the mouse PK studies, we also conducted a human 
plasma stability assay (Figure 4-3A). Confusingly, we found that TRX-PANO is entirely 
stable in human plasma up to six hours. This lead us to perform a literature review on 
hydrolases found in mice that are not present, or are present at significantly lower levels 
in humans, leading us to the esterase CES1c.10 This esterase is known to be extremely 
promiscuous, and importantly is found at highly elevated levels in mouse plasma while 
being virtually nonexistent in human plasma. A plasma stability assay was then 
performed with TRX-PANO in mouse plasma from wild type Black6 mice (WT) as well 
as those with plasma CES1 knocked out (CES1 KO). Pleasingly, TRX-PANO has a  
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Figure 4-3 a) Stability of TRX-PANO in human plasma. b) TRX-PANO is significantly more stable in CES1 
KO mouse plasma than wild type. c-d) Mice were injected with a single dose of TRX-PANO (15 mpk, IP). 
Plasma was collected at indicated times and plasma drug concentration was determined by LCMS/MS 
assay (IAS, Berkeley). TRX-PANO is unstable in NSG mice and is observed to be significantly more 
stable in CES1 KO mice. 
 
significantly prolonged half-life in CES1 KO mice compared to WT, indicating the 
esterase CES1 as the primary mechanism of instability in NSG mice (Figure 4-3B). A 
pharmacokinetic assay was then performed in CES1 KO mice which showed 
significantly improved pharmacokinetic parameters compared to wild type (Figure 3d). 
Initial in vivo efficacy of TRX-PANO appears encouraging 
Unfortunately, the CES1 KO mice used for pharmacokinetic studies were of a Black6 
background and were therefore unsuitable for xenograft studies with the human cancer 
cell lines of interest. Several mouse cancer cell lines were obtained to test for xenograft 
candidates, however Panobinostat proved to be at minimum two orders of magnitude 
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less efficacious in all mouse lines than in human multiple myeloma lines. At this point, a 
paper was published describing the generation of a NOD-SCID CES1 KO mouse line.11 
Two females and one male were purchased from Synthon Biopharmaceuticals and 
plasma CES1c KO was confirmed by DNA gel (data not shown). To assess this strain’s 
ability to bear a human multiple myeloma xenograft, both NSG and CES1KO NOD-
SCID mice were injected with 106 cells of MM.1S cells. While MM.1S.luc cells rapidly 
expands in NSG mice (observed by increased luminescence), the xenograft failed to 
take in CES1KO NOD-SCID mice (Figure 4-4A). While multiple myeloma is the  
 
 
Figure 4-4: a) NSG and CES1KO NOD-SCID mice were implanted with 10x MM.1S.luc cells. After 22 
days, no luminescence is seen in NOD-SCID mice indicating a lack of xenograft. b)  Mice were implanted 
with MDA-MB-231 cancer cells. Again, it appears xenografts do not grow well in CES1KO NOD-SCID 
mice.c) CES1KO mice bearing MDA-MB-231 xenograft tumors were dosed with TRX-PANO (20mpk), 
PANO (3mpk) or vehicle (n=2 for each arm) beginning on day 21. 
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preferred model system as it is the indication Panobinostat is approved for, there is 
literature suggesting it has significant activity against triple negative breast cancer.12 
The antiproliferative activity of Panobinostat and TRX-PANO were confirmed in MDA-
MB-231 cells (data not shown). This triple negative breast cancer cell line was able to 
expand in the NOD-SCID mice, albeit significantly less than in NSG mice (Figure 4-4B). 
These mice (n=2) were then dosed with TRX-PANO, Panobinostat, or vehicle for four 
weeks. While it appears both TRX-PANO and Panobinostat provide anti-tumor activity, 
the sample size prevents any meaningful conclusions to be drawn from this experiment. 
CONCLUSIONS AND FUTURE DIRECTIONS 
Future Directions  
There are two major future directions for this project: 1) improve the in vivo experiments 
by increasing sample size and/or solving the MM.1S xenograft issue. 2) Perform in vitro 
experiments to prove TRX-PANO cages known off-target toxicities of Panobinostat. 
Improving in vivo experiments 
While the preliminary results are somewhat encouraging, there is significant room for 
improvement in the future. Firstly, meaningful conclusions cannot be drawn from a 
sample size of two. This can be remedied by repeating the experiment with more mice, 
however this has proven difficult due to the problems faced with breeding (slow 
breeding time, small litter size) leading to not having enough females for breast cancer 
xenografts. A more appealing solution is to solve the issues with the MM.1S.luc 
xenograft experiments as it is sex-agnostic. One hypothesis is that because NOD-SCID 
mice have intact NK cells, the injected cells were primarily killed by the immune system 
		 74	
and therefore did not expand. A simple experiment is a dose-escalation of increasing 
concentrations of cancer cells.  
 
Demonstrating caged toxicity in vitro 
Other than simple bodyweight measurements, the clinical toxicities of Panobinostat do 
not manifest in in vivo experiments until testing in rats or dogs. As our lab only has 
access to mice, this limits our ability to show meaningful caging of the off-targets of 
Panobinostat. One side effect observed in the clinic is a drop in non-red blood cell 
counts.2 To determine if TRX-PANO shows caged activity against this target, PBMCs 
were treated in dose response with both TRX-PANO and Panobinostat for 72 hours. 
However, it was determined that neither TRX-PANO nor parent Panobinostat have 
cytotoxic activity against these cell types in vitro (Figure S4-2). 
Moving forward, there are two in vitro toxicity assays for which Panobinostat reportedly 
failed in its IND form: the Ames test and the COMET assay.(cite) The COMET assay 
tests if a compound causes DNA fragmentation in cell culture while the Ames test 
determines if a compound is mutagenic in the S.Typhimurium strain TA97a. A potential 
difficulty of these assays is both systems are known to have sufficient Fe(II) to uncage 
trioxolane-based prodrugs, though to varying degrees. A key inclusion for these 
experiments is to incubate the system with DFO or other iron chelator to minimize TRX 
uncaging. 
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MATERIALS AND METHODS 
Cell Line and Cell Culture 
MM.1S, RPMI 8226 and U266 cells were maintained in an atmosphere of 5% CO2 in 
RPMI 1640 media purchased from HyClone supplemented with 10% FBS (Gibco) and 
Pen/Strep (1× final concentration, Gemini BioProducts).  
 
In vitro inhibition 
In vitro inhibition was determined using the HDAC-Glo I/II screening system (Promega). 
Compounds were dissolved in DMSO then diluted in buffer to give a final concentration 
of 0.1% DMSO. Signal was read using the Flexstation 3 (Molecular Devices) 
 
Western Blots 
Cells were plated in 6-well plate at 106 cells per well and incubated for at least 24 h prior 
to exposure to compounds. Cells were then treated with specified concentrations of 
compound that resulted in a final concentration of 0.1% DMSO. After the specified 
amount of time, cells were pelleted by centrifuging at 200 x g for 5 minutes. Cell pellets 
were washed with PBS and then lysed with mPER lysis buffer (Thermo Fisher) 
containing protease inhibitor cocktail (1x concentration, Sigma). Protein concentration 
was determined using Pierce BCA assay (Thermo Fisher). Samples were normalized to 
20 µg per well and run on a 4-12% Bis-Tris Protein Gel (Thermo Fisher). Transfer and 
blotting was performed using the iBlot 2 and iBind system (Thermo Fisher)  
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Cell toxicity assay 
Cells were plated in 96-well Greiner black µClear tissue culture plates at 104 cells per 
well for at least 24 h prior to exposure to compounds. Cells were then treated in 
triplicate with escalating concentrations of compound performed in media containing a 
final concentration of 0.1% DMSO and 200 µL of media per well. Cell viabilities were 
determined 72 h after treatment by Cell-Titer Glo assay (Promega) on the Flexstation 3 
reader (Molecular Devices). Relative luminescent units (RLU) were plotted against 
corresponding drug concentrations and fitted with a standard four-parameter sigmoidal 
curve with GraphPad Prism 6. Data reported at the IC50, and error bars represent SEM. 
 
Plasma Stability Assay 
CES1 KO Black6 mouse plasma was graciously gifted from Dr. Barbara Slusher (John’s 
Hopkins, MD). To mouse plasma warmed to 37°C was added TRX-PANO in DMSO to 
give a final concentration of 10 µM with 0.1% DMSO. Aliquots were taken at 0, 30 & 60 
minutes and immediately extracted with acetonitrile. The organic layers were collected 
and compound concentration were determined by mass spectrometry.  
 
Pharmacokinetic Assays 
NSG, CES1KO Black6, or CES1KO NOD-SCID mice were administered a single IP 
dose of TRX-PANO (17.5 mpk, n=3). Blood was collected at indicated timepoints and 
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from which drug concentrations were determined by Integrated Analytical Solutions, Inc 
(Berkeley, CA). 
 
Mouse efficacy 
Mice were implanted with 106 MDA-MB-231 cells. Once tumor volumes reached 
approximately 100 cm3, mice were administered IP doses of TRX-PANO (20 mpk), 
Panobinostat (3 mpk), or vehicle three days per week for four weeks. Efficacy was 
measured by monitoring tumor volume. 
 
Mouse Genotyping 
Tails were collected from three CES1 KO NOD-SCID mice purchased from Synthon 
Biopharmaceuticals. DNA was extracted by boiling in 25 mM NaOH and 0.2 mM EDTA. 
The pH of this solution was adjusted to 5.5 by addition of 40 mM Tris HCl (pH 5.5) and 
the resulting solution was centrifuged at 4000 rpm for 3 minutes. PCR was performed 
on the supernatant followed by gel electrophoresis to confirm complete CES1 knockout. 
 
Other 
Graphing and analysis of data were done using GraphPad Prism 6 software and 
Microsoft Excel 2010. Figures were prepared with Adobe Design Standard CS6 
software. 
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SUPPORTING INFORMATION 
Supplemental Figures 
 
Figure S4-1: In Vitro HDAC inhibition of HeLa nuclear extract. Panobinostat IC50 was consistent with 
literature values (5.5 nM). TRX-PANO showed reduced yet not fully masked activity in the in vitro setting 
(~125 µM). 
	
Figure S4-2: Cell viability of PBMCs after 72 hours of treatment. Panobinostat and TRX-PANO show 
negligible toxicity. 
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Synthesis 
Compound 1 (methyl(2E)-3-[4-({[2-(2-methyl-1H-indol-3-
yl)ethyl]amino}methyl)phenyl]prop-2-enoate) was synthesized as described in 
WO2007/21682. 2007, A1 
 
Compounds 6 (O-(dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1''-cyclohexan]-3''-
yl)hydroxylamine) was synthesized as previously described (ACS Inf Disease) 
 
 
methyl (2E)-3-[4-({N-[2-(2-methyl-1H-indol-3-yl)ethyl]4-
nitrobenzenesulfonamido}methyl)phenyl]prop-2‐enoate (2). To a round bottom 
flask equipped with an argon inlet adapter, stirbar, and rubber septum was charged a 
solution of 1 (2.78g, 7.98 mmol, 1 equiv.) in dichloromethane (80 mL). This solution was 
cooled to 0°C, at which point triethylamine (1.67mL, 11.98 mmol, 1.5 equiv.), 4-
dimethylaminopyridine (97.5mg, 0.80 mmol, 0.1 equiv.) and 4-nitrobenzenesulfonyl 
chloride (1.95g, 8.77 mmol, 1.1 equiv.) were added sequentially. This cloudy orange 
mixture was allowed to warm to room temperature overnight then organic solvent was 
removed under vacuum to give an orange solid. This was then dissolved in 200 mL of 
EtOAc and washed with two 100 mL portions of satd. aq. NaHCO3 each. The aqueous 
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layer was then extracted with two 100 mL portions of EtOAc. Organic layers were 
combined and washed with one 100 mL portion of satd. aq NaCl, dried over MgSO4, 
filtered and solvent removed under vacuum to afford methyl (2E)-3-[4-({N-[2-(2-
methyl-1H-indol-3-yl)ethyl]4-nitrobenzenesulfonamido}methyl)phenyl]prop-2‐
enoate (4.25g, quant.) as a bright orange solid. MS (ESI) calculated for C28H27N3O6S 
[M + H]+ m/z 534.17, found 534.08. 
 
 
(2E)-3-[4-({N-[2-(2-methyl-1H-indol-3-yl)ethyl]4-
nitrobenzenesulfonamido}methyl)phenyl]prop-2-enoic acid (3). To a round bottom 
flask equipped with an argon inlet adapter, stirbar, and rubber septum was charged a 
solution of 2 (4.25g, 7.98 mmol, 1 equiv.) in THF (50 mL) and MeOH (50 mL). To this 
suspension was added 1M LiOH in water (50 mL, 47.9 mmol, 6 equiv,). This suspension 
was then stirred at 50°C for 16 hours at which point organic solvent was removed under 
vacuum. This was then dissolved in 200 mL of EtOAc and 50 mL of water and cooled to 
0°C before adjusting the pH to 1 through addition of 10% aq. HCl. The organic layer 
was collected and washed with two 50 mL portions of 1M aq. HCl. The aqueous layer 
was then extracted with two 500 mL portions of EtOAc. Organic layers were combined 
and washed with one 100 mL portion of satd. aq NaCl, dried over MgSO4, filtered and 
solvent removed under vacuum to afford (2E)-3-[4-({N-[2-(2-methyl-1H-indol-3-
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yl)ethyl]4-nitrobenzenesulfonamido}methyl)phenyl]prop-2-enoic acid (4.13g, 97%) 
as a bright orange solid. 1H NMR (400 MHz, DMF-d7) δ ppm 2.32 - 2.43 (m, 3 H) 3.02 - 
3.08 (m, 3 H) 3.43 - 3.58 (m, 3 H) 4.82 (s, 2 H) 6.79 (d, J=16.07 Hz, 1 H) 7.00 - 7.12 (m, 
2 H) 7.29 - 7.39 (m, 2 H) 7.68 (d, 2 H) 7.77 - 7.89 (m, 1 H) 7.92 (m, 2 H) 8.22 - 8.31 (m, 
2 H) 8.50 - 8.56 (m, 2 H) 10.80 (s, 1 H). MS (ESI) calculated for C27H25N3O6S [M + H]+ 
m/z 520.15, found 520.09. 
 
 
(2E)-N-{dispiro[adamantane-2,2'-[1,2,4]trioxolane-4',1''-cyclohexan]-3''-yloxy}-3-[4-
({N-[2-(2-methyl-1H-indol-3-yl)ethyl]4-
nitrobenzenesulfonamido}methyl)phenyl]prop-2-enamide (4). To a round bottom 
flask equipped with an argon inlet adapter, stir bar, and rubber septum was charged a 
solution of 6 (113.3mg, 0.38 mmol, 1 equiv.) in DMF (8 mL) and a solution of 3 (230mg, 
0.44 mmol, 1.15 equiv.) in DMF (8 mL). To this solution was added 1-
hydroxybenzotriazole hydrate (68mg, 0.50 mmol, 1.3 equiv.), N,N-diisopropylethylamine 
(0.08 mL, 1.01 mmol, 2.6 equiv.) then N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (96mg, 0.50 mmol, 1.3 equiv.) sequentially. This deep orange solution 
stirred at rt for 16 hours at which point the reaction was diluted with 50 mL of EtOAc and 
50 mL of satd. aq. NaHCO3.The organic layer was collected and washed with two 50 
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mL portions of satd. aq. NaHCO3. The aqueous layers were then combined and 
extracted with two 50 mL portions of EtOAc. Organic layers were combined and washed 
with one 50 mL portion of satd. aq NaCl, dried over MgSO4, filtered and solvent 
removed under vacuum to afford an orange oil. The residue was then purified through 
flash column chromatography (0-40% EtOAc/Hexanes) to yield (2E)-N-
{dispiro[adamantane-2,2'-[1,2,4]trioxolane-4',1''-cyclohexan]-3''-yloxy}-3-[4-({N-[2-
(2-methyl-1H-indol-3-yl)ethyl]4-nitrobenzenesulfonamido}methyl)phenyl]prop-2-
enamide (226mg, 74%). 1H NMR (400 MHz, DICHLOROMETHANE-d2) δ ppm 1.23 - 
1.48 (m, 3 H) 1.64 - 1.89 (m, 12 H) 1.89 - 2.02 (m, 4 H) 2.06 - 2.22 (m, 3 H) 2.26 - 2.41 
(m, 1 H) 2.68 - 2.80 (m, 2 H) 3.23 - 3.36 (m, 2 H) 3.97 (s, 1 H) 4.41 - 4.50 (m, 2 H) 6.92 
- 7.04 (m, 2 H) 7.14 (d, 2 H) 7.28 - 7.46 (m, 2 H) 7.46 - 7.54 (m, 2 H) 7.54 - 7.74 (m, 1 
H) 7.85 (d, 2 H) 7.94 - 8.10 (m, 1 H) 8.17 (d, 2 H)). 13C NMR (100 MHz, 
DICHLOROMETHANE-d2) δ ppm 11.71, 20.17, 24.31, 27.11, 27.50, 29.84, 34.34, 
35.24, 35.33, 36.88, 36.98, 37.17, 39.49, 48.64, 52.31, 54.39, 107.86, 109.45, 110.85, 
112.18, 117.81, 119.70, 121.50, 124.66, 128.45, 129.55, 132.42, 135.70, 146.04, 
150.23. MS (ESI) calculated for C43H48N4O8S [M - H]- m/z 795.31, found 795.56. 
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(2E)-N-{dispiro[adamantane-2,2'-[1,2,4]trioxolane-4',1''-cyclohexan]-3''-yloxy}-3-[4-
({N-[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide (5, TRX-
PANO). To a round bottom flask equipped with an argon inlet adapter, stirbar, and 
rubber septum was charged a solution of 4 (207mg, 0.26 mmol, 1 equiv.) in DMF (12 
mL). To this solution was added CsCO3 (507mg, 1.55 mmol, 6 equiv,) and thiophenol 
(0.106mL, 1.04 mmol, 4 equiv.). This suspension was then stirred at rt for 16 hours at 
which point the reaction was diluted with 50 mL of EtOAc, 30 mL of satd. aq NaHCO3 
and 20 mL of water. The organic layer was separated and washed with two 50 mL 
portions of satd. aq NaHCO3. The aqueous layers were combined and extracted with 
two 50 mL portions of EtOAc. Organic layers were combined and washed with one 100 
mL portion of satd. aq NaCl, dried over MgSO4, filtered and solvent removed under 
vacuum to afford a yellow oil. The residue was then purified through flash column 
chromatography (0-10% MeOH/CH2CL2) to yield (2E)-N-{dispiro[adamantane-2,2'-
[1,2,4]trioxolane-4',1''-cyclohexan]-3''-yloxy}-3-[4-({N-[2-(2-methyl-1H-indol-3-
yl)ethyl]amino}methyl)phenyl]prop-2-enamide (117mg, 74%). 1H NMR (400 MHz, 
METHANOL-d4) δ ppm 1.19 - 1.42 (m, 3 H) 1.55 - 1.82 (m, 13 H) 1.82 - 2.02 (m, 7 H) 
2.06 - 2.13 (m, 1 H) 2.32 (s, 3 H) 2.36 - 2.43 (m, 1 H) 2.77 - 2.87 (m, 2 H) 2.87 - 2.97 
(m, 2 H) 3.76 (s, 2 H) 3.82 - 3.94 (m, 1 H) 6.43 (d, J=15.71 Hz, 1 H) 6.86 - 7.03 (m, 2 H) 
7.23 (dd, J=7.97, 4.57 Hz, 3 H) 7.33 - 7.41 (m, 1 H) 7.44 (br d, J=8.04 Hz, 2 H) 7.56 (d, 
J=15.71 Hz, 1 H). 13C NMR (100 MHz, METHANOL-d4) δ ppm 11.57, 14.61, 20.94, 
24.84, 28.03, 28.43, 30.60, 34.99, 35.88, 37.83, 37.88, 37.92, 40.59, 50.27, 53.79, 
61.66, 82.88, 108.65, 110.36, 111.53, 112.66, 118.24, 118.53, 119.66, 121.58, 129.19, 
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129.93, 130.21, 133.32, 135.29, 137.26, 142.00, 142.23, 166.60. MS (ESI) calculated 
for C37H45N3O5 [M + H]+ m/z 612.34, found 612.23.  
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Chapter 5: Future Directions 
	
While this work has suggested a connection between KRAS mutations and an elevated 
labile iron pool, this by no means tells the complete story. Iron homeostasis is a highly 
complex and regulated system, and we plan to probe how different genes affect this 
network. To do so, we propose to perform a TRX-based CRISPRi and CRISPRa screen 
on various genes thought to be involved in iron metabolism. The system to be used is a 
Tet-on GFP reporter, in which introduction of tetracycline (or similar analogs) will cause 
the production of cellular GFP. We first caged doxycycline with the TRX platform so that 
it may not interact with the Tet-promoter unless reacted first with Fe(II) (Scheme 5-1).  
	
Scheme 5-1: Synthesis of TRX-DOX. Racemic TRX or DXL alcohol in pyridine and THF was 
cooled before activation with phosgene. After 2 hours, the chloroformate was reacted with 
excess doxycycline to produce TRX- and DXL-DOX. Stereochemistry is based on literature and 
is currently unconfirmed. 
As TRX-DOX is formed through a carbonate linkage as opposed to the traditional 
carbamate, DXL-DOX was synthesized as well as a control for carbonate stability in 
cells. Tet-on GFP K562 cells were then dosed with varying concentrations of 
doxycycline (DOX), TRX-DOX, and DXL-DOX. Pleasingly, cells dosed with DXL-DOX 
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showed no GFP signal, indicating the carbonate linkage of TRX-DOX both disrupts 
interaction with the Tet promoter and is stable in these cells (Fig 5-2A). At the same 
time, TRX-DOX shows a dose-dependent increase in GFP signal consistent with 
increasing delivery of doxycycline. Importantly, the amount of GFP expressing cells 
increases upon iron preloading and decreases upon iron withholding (Figure 5-2B,C). 
These probes along with the Tet-on GFP cells allow us to measure changes in labile 
iron pool concentrations in a high-throughput CRISPR screen. 
	
Figure 5-1 a) K562 cells with dox-inducible GFP were dosed with Dox, TRX-DOX and DXL-DOX 
at varying concentrations. TRX-DOX shows dose-dependent activation of GFP while DXL-Dox 
remains inactive indicating ample caging. b) Cells were pretreated with either FAC (500 µM), 
DFO (300 µM), or DMSO (0.1%) for 2 hours before dosing. DFO appears to reduce GFP signal 
in both treatments while FAC increases only in TRX-DOX treated cells. c) Normalized signal 
from B. TRX-DOX normalized to free DOX. Then, DFO or FAC normalized to cells pretreated 
with DMSO. 
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